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Sommario  
 
Il Fattore H del complemento (FH) è un importante regolatore della via alternativa 
del complemento: protegge infatti le cellule dell’ospite dall’attacco del sistema del 
complemento e carenze di FH sia qualitative e quantitative dovute a mutazioni nel 
gene CFH sono spesso associate ad una serie di malattie umane, come la 
glomerulonefrite membranoproliferativa (MPGN), la sindrome emolitico-uremica 
atipica (aHUS) e la degenerazione maculare della retina legata all’età (AMD). 
Mentre esiste una caratterizzazione genetica per tutte queste malattie, i dati 
funzionali a livello di proteine sono spesso carenti. 
Inoltre, il FH gioca un ruolo significativo nelle malattie infettive: molti agenti 
patogeni sono infatti in grado di reclutare il FH sulla loro superficie sfruttandolo per 
proteggersi dagli attacchi del complemento. Mentre per alcuni agenti patogeni 
l'interazione con il FH è stata ben descritta, per gli altri gli "interattori" diretti sono 
ancora sconosciuti. 
Tuttavia, lo studio del FH è complicato dalla presenza di proteine FH-related 
(FHRs) che posseggono un elevato grado di somiglianza con il FH e ne rendono 
quindi difficile la purificazione e la analisi diretta.  
Il primo obiettivo di questo progetto è stato lo sviluppo di saggi quantitativi e 
funzionali FH-specifici, utilizzando un anticorpo monoclonale (Mab 5H5) prodotto 
nel nostro laboratorio, che si è dimostrato essere specifico per FH. Il secondo era 
la produzione del FH intero e di tre frammenti, contenenti diverse porzioni della 
proteina, sia in un sistema di espressione eucariotico che procariotico.  
L’anticorpo 5H5 è stato prodotto in grandi quantità utilizzando un mini-fermentatore 
ed è stato utilizzato per purificare il FH mediante cromatografia di affinità. La 
purezza e l’attività funzionale del FH purificato sono state valutate e confrontate 
con gli altri metodi di purificazione (ad es. affinità su Eparina, HPLC, HIC). 
È stato inoltre sviluppato un test ELISA per la corretta quantificazione del FH da 
fluidi biologici, utilizzando il 5H5 insieme ad un anticorpo policlonale anti-FH, 
anch’esso prodotto nel nostro laboratorio, e al FH purificato per affinità. Questo test 
di quantificazione è risultato affidabile ed è stato utilizzato per valutare diversi 
campioni di pazienti aHUS e AMD.  
Inoltre, sono stati sviluppati anche due micro-metodi di purificazione del FH. Questi 
metodi consentono di purificare una buona quantità di FH altamente purificato 
partendo da una piccola quantità di campione e sono quindi uno strumento utile 
per studiare il FH specialmente in quelle patologie, quali aHUS, che colpiscono 
soprattutto i bambini. 
Infine, sono stati sviluppati due saggi funzionali per valutare sia l'attività cofattoriale 
N-terminale che l’attività protettiva C-terminale del FH. Il FH è una grossa 
glicoproteina solubile che possiede funzioni diverse in differenti parti della 
molecola. Quindi diversi test sono necessari per valutare la completa funzionalità 
del FH. 
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Il primo test, il "cofactor assay", basato sul fatto che il FH possiede attività 
cofattoriale per il taglio del C3b mediato dal FI, è completamente funzionante ed è 
già stato utilizzato per lo screening di diversi campioni. 
Il secondo, il test di emolisi, si basa sul fatto che il FH è in grado di proteggere gli 
eritrociti di pecora dalla emolisi mediata dal complemento. In questo test il FH 
purificato dai pazienti verrà utilizzato insieme ad un siero di controllo depleto di FH, 
al fine di avere un saggio in cui l'unica variabile sia il FH. Questo test è stato già 
messo a punto utilizzando un siero di controllo al fine di verificare tutte le 
condizioni, ed è ora nella fase finale di sviluppo, dopo di che sarà utilizzabile su 
materiale dei pazienti. 
I quattro cloni contenenti la sequenza completa del FH e i frammenti parziali (SCRs 
1-7, SCRs 8-14, SCRs 15-20) sono stati prodotti e saranno utilizzati per esprimere 
FH sia in forma glicosilata che non glicosilata. Sarà quindi analizzata la capacità di 
queste proteine ricombinanti di interagire con le proteine dei patogeni o di 
ripristinare la funzione di un FH difettoso. 
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Abstract 
 
Complement Factor H (FH) is a major regulator of the Alternative Pathway of 
Complement: it protects host cells from complement attack and qualitative and 
quantitative deficiencies of FH due to mutations in the CFH gene are frequently 
associated with a number of human diseases, such as membranoproliferative 
glomerulonephritis (MPGN), atypical haemolytic uraemic syndrome (aHUS) and 
age-related macular degeneration (AMD). A genetic characterisation is available for 
all these diseases, whereas functional data on protein levels are often missing. 
Furthermore, FH plays a significant role in infectious diseases, as many pathogens 
are able to recruit FH on their surface, thus protecting themselves from 
complement attack. Whereas interaction of FH with certain pathogens has been 
well described, for others the direct “interactors” still remain unknown. 
However, the study of FH is complicated by the presence of FH-related proteins 
(FHRs) that share a high degree of similarity rendering its purification and direct 
analysis challenging. 
The first focus of this project was the development of quantitative and functional 
FH-specific assays, using a monoclonal antibody (MAb 5H5) produced in our 
laboratory, which has been shown to be specific for FH. The second aim was the 
production of the whole recombinant FH and of three fragments, containing 
different parts of the protein, in both a eukaryotic and a prokaryotic expression 
system. 
MAb 5H5 was produced in high amounts using a mini-fermentator and used to 
purify FH by affinity chromatography. Purity and functional activity of this affinity-
purified FH were assessed and compared with FH obtained by other purification 
methods (eg. Heparin affinity, HPLC, HIC). 
An home made ELISA for the correct quantification of FH from biological fluids, 
making use of 5H5 together with a polyclonal anti-FH antibody, also produced in 
our lab, and affinity purified FH was also developed. This reliable quantification 
assay was used to screen samples from aHUS and AMD patients. 
Moreover, two micro-methods to purify FH were also developed. These methods 
enable to purify a good quantity of highly purified FH from a small amount of 
sample and are therefore a useful tool to study FH especially in those pathologies, 
such as aHUS, which mainly affect children. 
Finally, two functional assays to assess both the N-terminal cofactorial activity and 
C-terminal protective activity of FH have been set up. FH is a big soluble 
glycoprotein that bears different functions in different parts of the molecule. 
Therefore different tests are needed to assess full functionality of FH. 
The first test, the “cofactor assay”, based on the fact that FH possesses cofactor 
activity for the FI-mediated cleavage of C3b, is now fully implemented and has 
already been used to screen different samples. 
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The second one, the “haemolysys test” is based on the fact that FH is able to 
protect sheep erythrocytes from haemolysis mediated by complement. In this test 
FH purified from patients will be used together with a control FH-depleted serum, in 
order to set up an assay where the only variable is FH. This test has already been 
set up with a control serum in order to test all the conditions, and is now in its fine 
tuning phase, after which it will be applicable to patient’s material. 
The four clones containing the complete FH sequence and partial fragments (SCRs 
1-7, SCRs 8-14, SCRs 15-20) have been produced and will be used to express FH 
in a glycosylated or unglycosylated form. These recombinant proteins will be 
screened for their ability to interact with proteins from pathogens or to restore the 
function of a defective FH. 
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ABBREVIATIONS 
aHUS atypical Hemolitic Uremic Syndrome 
AMD Age-related Macular Degeneration 
AP Alternative Pathway 
AP Alkaline Phosphatase 
BCIP 5-bromo-4-chloro-3'-indolyphosphate p-toluidine 
C1-INH C1 inhibitor 
C4bp C4 binding protein  
CA Cofactor activity 
CD Cluster of differentiation 
CFH Factor H gene 
CFHRs Factor H related proteins genes 
C Complement 
C“n” Complement component (from 1 to 9) 
Cn Clusterin(SP-40,40, apolipoprotein J) 
CP Classical Pathway 
CR1 Complement receptor 1 
CR2 Complement receptor 2 
CRP C-reactive protein  
DAA Decay accelerating activity 
DAF Decay-accelerating factor 
DDD Dense deposit disease 
ELISA Enzyme-linked immunosorbent assay  
ESh Sheep erythrocyte 
FB Factor B 
FD Factor D  
FH Factor H 
FHL-1 Factor H-like protein 1  
FHRs Factor H related proteins 
FI Factor I 
GAG Glycosaminoglycan 
GlcNAc N-acetyl-glucosamine 
GalNAc N-acetyl-galactosamine 
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GBM Glomerular basement membrane  
GPI Glycosylphosphatidylinositol  
HRP Horseradish Peroxidase  
iC3b Inactive C3b 
iC4b Inactive C4b 
Ig Immunoglobulin 
IP Immunoprecipitation 
LP Lectin Pathway 
LPS Lipopolysaccharide  
MAb Monoclonal antibody 
MAC Membrane attack complex 
MASPs MBL-associated serine proteases  
MBL Mannose-binding lectin  
MCP Membrane cofactor protein 
NBT nitro-blue tetrazolium chloride 
P Properdin 
PAb Polyclonal antibody 
RCA  Regulators of complement activation 
RPE Retinal pigment epithelium 
SCR  Short consensus repeat domain 
SDS-PAGE  Sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis 
SPR  Surface Plasmon resonance 
TM Thrombomodulin  
TMB Tetramethylbenzidine 
Vn Vitronectin (S-protein) 
WB Western Blot 
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INTRODUCTION 
1. The complement system 
The complement system is a central component of innate immunity and is 
one of the principal mechanisms of defence against infections. 
Complement was first identified in the 1890s by Jules Bordet as a heat-
labile principle in serum that “complemented” antibodies in the killing of 
bacteria [1, 2]. Now we know that it consists of more than 30 soluble 
plasma and membrane-associated proteins interacting with each other to 
activate and regulate the system [3]. 
The complement system has three main physiologic activities: defence 
against bacterial infection, bridging of innate and adaptive immunity, and 
disposal of immune complexes and the products of inflammatory injury [4].  
The activation of complement consists in an enzymatic cascade in which 
complement proteins, normally present in serum as inactive enzyme 
precursors (zymogens), are activated sequentially. Each component 
recognises and activates, generally by proteolysis, the following one. 
Complement can be activated by three different pathways: the classical 
(CP), the lectin (LP) and the alternative (AP) pathways, according to the 
nature of recognition [5]. All these pathways converge after the activation 
of the central component C3 and are followed by a common non-
enzymatic process consisting on the assembly of a cytolytic complex named 
the “membrane attack complex” (MAC), which forms a hole in the 
membrane and initiates cell lysis [6, 7]. 
Control of these enzymatic cascades is essential to prevent rapid 
consumption of complement in vivo, therefore a group of plasma and 
membrane-bound proteins act to inhibit the system at multiple stages. 
Some of the proteolytic complement protein fragments, such as C3b, are 
also able to opsonize microbes thus stimulating phagocytosis and B-cell 
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responses, whereas other fragments, named “anaphylatoxins”, can attract 
and activate macrophages and neutrophils to the site of infection [8–10]. 
Two other important roles of the complement system are the clearance of 
apoptotic and necrotic cells by promoting their phagocytosis and the 
clearance of immune complexes from circulation by solubilizing and 
transporting them to the reticuloendothelial system [11, 12]. 
1.1. Complement activation 
Depending on the stimuli, complement activation can follow three 
different pathways (Fig.1): 
- Classical Pathway is activated by surface-bound antibodies (IgM and 
certain isotypes of IgG) 
- Alternative Pathway is constitutively active but can be enhanced by 
certain molecules (carbohydrates, lipids or proteins) bound to foreign 
surfaces. 
- Lectin Pathway is stimulated by the mannose-binding lectin (MBL) 
bound to mannose residues on the pathogen surface 
 
Fig. 1 Schematic representation of the activation of complement cascade. 
After recognizing the target all the three pathways converge to covalent attachment 
of C3b on the surface.  
The names classical and alternative arose because the classical pathway 
was discovered first but the alternative pathway is phylogenetically older. 
All the pathways converge in the formation of an enzymatic complex called 
C3-convertase, composed of different parts in the various pathways but all 
with the same target, the molecule C3 which is hydrolysed into C3b and 
covalently attached to the target cell surface. 
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1.1.1. Classical Pathway 
The Classical Pathway was the first one to be discovered, its components 
are designated from C1 through C9 in the order they were discovered but 
this does not quite correspond with the order of the reactions. 
This pathway is initiated by the first component of complement system, C1, 
which is a  macromolecular complex consisting of C1q and two molecules 
each of the proteases C1r and C1s, held together in a complex (C1qr2s2) 
stabilized by Ca
2+
. C1q is composed of 18 polypeptide chains which form six 
monomers, composed of a collagen-like tail and a fibrinogen-like head 
domain, that associate in a "bouquet of tulips"-like configuration [13]. 
The pathway can be initiated in an Ab-dependent manner when C1q 
interacts with clusters of IgG1 or IgG3, or IgM on microbial surfaces or in 
immune complexes. The classical pathway can be initiated also in an Ab-
independent manner occurring when C1q reacts directly with C-reactive 
protein (CRP) bound to apoptotic cells, or with polyanions (eg. heparin, 
protamine, DNA and RNA) displayed on their surface or when it interacts 
with lipopolysaccharide (LPS) on microbial surfaces [14–16]. 
Binding of C1q to its targets induces a conformational change in C1r that 
converts it into an active serine protease enzyme, which then cleaves C1s 
to a similar active enzyme [17]. Active C1s enzyme cleaves plasma C4 to 
C4a and C4b; the smaller fragment C4a has been shown to be an 
anaphylatoxin though considerably less active than are C3a and C5a [18, 
19]. The bigger fragment C4b attaches to the target surface in the vicinity 
of C1, and acts as an acceptor for the next complement protein, C2. After 
the interaction with the cell surface–bound C4b, C2 is cleaved by C1s and 
generates two fragments: a smaller soluble fragment named C2b with 
unknown activity and a larger C2a fragment that remains physically 
associated with C4b on the cell surface, forming the C4b2a complex that is 
the classical pathway C3 convertase. (Note: the nomenclature of C2 
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fragments is different from the other complement proteins as for historical 
reasons the attached bigger fragment was called “a” and the released one 
“b”. An attempt to reverse these “a” and “b” designations was not 
universally accepted by experts in the complement field leading to 
confusion in textbooks and scientific literature) [20].  
The classical pathway C3 convertase binds C3 thanks to the C4b 
component whereas the C2a component catalyses its proteolysis into C3a 
and C3b [21]. The small C3a fragment is an anaphylatoxin that stimulates 
inflammation [10]. The bigger fragment, C3b, can diffuse away and form 
covalent bonds with cell surfaces or with the antibody where complement 
activation was initiated, functioning as an opsonin, or it can remain bound 
to the complex to form a trimolecular complex C4b2a3b, called the 
classical pathway C5 convertase. 
1.1.2. Alternative Pathway 
The Alternative Pathway results in the proteolysis of C3 as the Classical 
Pathway does but without any need for antibody for initiation. This 
pathway of complement activation requires only four serum proteins: C3, 
factor B (FB), factor D (FD), and properdin (P) [22]. 
This pathway is normally constitutively active: C3 in plasma is in fact being 
continuously cleaved at a low rate to generate C3b in a process that is 
called “tick-over”. C3 is spontaneously converted to metastable C3* that 
undergoes hydrolysis to form C3(H2O) which in turn interacts with factor B 
forming the initial convertase [23]. The complex C3(H2O)B is a target for 
factor D which cleaves factor B releasing the Ba fragment and forming the 
enzyme C3(H2O)Bb. The enzyme C3(H2O)Bb has a short half-life (90 sec.) but 
can be stabilized by the binding of properdin that acts as a positive 
regulator of complement [24]. C3(H2O)Bb is a C3 convertase enzyme that 
cleaves C3 to C3a and to metastable C3b* that exposes a highly reactive 
thioester bond. The thioester domain can react with the amino or hydroxyl 
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groups of cell surface proteins or polysaccharides enabling C3b to become 
covalently attached to cell surfaces [25].  If these bonds are not formed, 
the C3b remains in the fluid phase, where is quickly hydrolysed and can 
form with FB the fluid phase C3b(H2O)Bb that can cleave more C3. The C3b 
bound to the membrane can react with FB which is cut by FD with the 
release of Ba and the formation of the complex C3bBb that is the 
alternative pathway C3 convertase (Fig.2). C3bBb can cleave more C3 
molecules, thus generating an amplification loop. Some of the C3b 
molecules originated can then bind to the convertase itself leading to the 
formation of the complex C3bBbC3b, which is the alternative pathway C5 
convertase. 
 
Fig. 2 Schematic representation of the AP activation. Details are discussed in 
the text. 
1.1.3. Lectin Pathway  
The lectin pathway is initiated in the absence of antibody by the binding of 
microbial polysaccharides to circulating lectins such as mannan-binding 
lectin (MBL) or ficolins (L, H or M). These soluble lectins are collagen-like 
proteins that structurally resemble C1q [26]. 
MBL, L-ficolin, and H-ficolin are plasma proteins whereas M-ficolin is 
mainly secreted by activated macrophages in tissues. These lectins are able 
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to recognize microbial sugar structures; MBL binds to mannose residues on 
glycoproteins or carbohydrates present on the surface of microorganisms 
whereas the ficolin fibrinogen-like domain can bind to different substances 
such as GlcNAc, GalNAc, fucose, sialic acid, lipoteichoic acid (LTA) [27, 28]. 
MBL and ficolins associate with MBL-associated serine proteases (MASPs) 
including MASP1, MASP2, and MASP3. The MASP proteins are structurally 
homologous to the C1r and C1s proteases and have a similar function but 
they are not able to bind C1q. 
MASP-1 can cleave very efficiently C2 but not C4, a weak activity in cutting 
C3 has also been shown, and also has a role in activating MASP-2; MASP-2 
can also cleave with a high efficiency C2 and to a lower extent C4; MASP-3 
does not cleave C2 or C4 and its function is still uncertain but it seems to 
activate FD in vitro [26, 29]. MASP proteins lead to the formation of the 
same C3 convertase of the classical pathway (C4b2a) and the rest of the 
pathways are identical. 
1.1.4. Properdin Pathway  
Properdin role in stabilizing components of the alternative pathway 
convertases has been shown since the 1970’s. More recently it has been 
discovered that properdin is also able to activate an “additional” pathway 
of complement that utilizes the same components as the alternative 
pathway, but that is initiated directly by properdin [30]. Properdin is able 
to bind directly to target cells and microbes, thus providing a platform for 
the assembly of convertase and leading to phagocytosis. Properdin bound 
on a surface has been shown to bind C3, the resulting C3bP complex can 
then bind factor B forming C3bBP that can in turn be cleaved by factor D, 
releasing Ba and generating surface-bound C3bBbP. This convertase is 
similar to the one of the alternative pathway, but its formation is initiated 
by properdin rather than nascent C3b [30]. The significance of this 
properdin-driven pathway is still elusive, but it has raised a lot of attention 
as a novel activation pathway. 
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1.2. The terminal pathway 
The C3 convertase of the CP and LP (C4b2a) or that of the AP (C3bBb) 
perform a proteolytic cleavage of C3, releasing a small fragment, C3a and 
producing C3b. The C3 convertase is able to activate more C3 molecules 
leading to an amplification step that is necessary for proceeding to the 
terminal pathway. The terminal pathway of complement starts when large 
amounts of C3b have been produced and some bind directly to the C3 
convertase forming the C5 convertase of the CP and LP (C4b2a3b) or that 
of the AP (C3bBbC3b) [31–33]. The addition of this C3b molecule on C3 
convertases changes the substrate specificity of the active sites, located in 
C2a and Bb, from C3 to C5 component. The C5 is then hydrolysed by the C5 
convertases forming the C5a and C5b fragments. C5a that is released to 
plasma is a powerful anaphylatoxin and chemotaxin, even more potent 
than C3a [34]. 
The generation of C5b activates a non-enzymatic process of assembling of 
the terminal complement components leading to the formation of the 
membrane attack complex (MAC) [6, 35]. C5b, which is extremely labile, 
serves as a platform for the sequential binding of C6 and C7 forming the 
C5b-7 complex. After the binding of C7, the C5b-7 complex becomes 
amphipathic and exposes hydrophobic regions which enable its insertion 
into the membrane [36]. C5b-7 anchored in the lipid bilayer is a receptor 
for plasma C8, the formed C5b-8 complex functions as receiver of multiple 
molecules of C9 (from 16 to 18) that create a cylindrical pore of about 30 
nm in the membrane [37, 38].The C5b-9 complex, also called membrane 
attack complex (MAC), allows the diffusion of small molecules across the 
membrane to occur, and leads to rapid osmotic lysis of the target cell [39, 
40].  
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2. Regulation of the complement system 
The complement system is the first line of defence against infections, it is 
rapidly activated and ends in the lysis of foreign cells. Activation of 
complement could also be potentially harmful to the individual so, in order 
to prevent unwanted damage to host cells, the complement system needs 
to be tightly regulated. Complement is regulated by a set of proteins, both 
circulating or membrane-associated, that act at different steps of the 
cascade and enable fine tuning of complement activation in different 
physiological circumstances. Regulators of the complement system ensure 
that the activation is both effective and localized on foreign surfaces. 
2.1. Regulatory proteins 
Most complement regulators are encoded by a gene cluster called RCA 
(regulators of complement activation), located on chromosome 1 in the 
region 1q32 [41] (Fig.3). 
 
 
Fig. 3 Structure of the RCA gene cluster on human chromosome 1. The RCA 
cluster is located on the long arm of chromosome 1, 1q32 region. Colored genes 
encode for proteins related to the regulation of the complement system. 
 
Genes for other complement regulators are spread throughout the 
genome, these include C1 inhibitor (C1-INH), CD59 (protectin), 
thrombomodulin (TM), vitronectin and clusterin. 
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2.2. Non-RCA regulators 
C1-INH is a 105 KDa single-chian glycoprotein that belongs to the 
superfamily of serine proteinase inhibitor (serpin). It’s composed of two 
domains: a C-terminal serpin domain that contains the protease 
recognition region and provides the inhibitory activity and an unique, 
heavily glycosylated N-terminal domain (~100 aa), not present in other 
serpins, that has no role in protease inhibition but is important in 
maintaining functional integrity [42]. 
C1-INH is the main regulator of both the CP and LP: it irreversibly binds and 
inactivates the serine proteases C1r, C1s [43] and MASP-1, MASP-2 [44]. 
C1-INH is the only plasma protease inhibitor of the CP, it disassembles C1 
dissociating C1r and C1s and it can also suppress spontaneous activation of 
C1 via a reversible interaction with zymogen C1r and C1s. It can also 
regulate the LP via inactivation of MASP2, although α2 macroglobulin also 
is able to inhibit MASP2 [45]. 
C1-INH is a suicide protease inhibitor that irreversibly binds to its targets, 
its reactive loop behaves as a pseudo-substrate for the protease that 
cleaves the peptide bond and covalently binds to the inhibitor. After 
binding, C1-INH acts as a mousetrap swinging the inactivated protease 
from the upper to the lower pole and inserting the reactive loop of the 
protease inside its structure [46]. 
C1INH is also the major inhibitor of factor XIIa and kallikrein of the contact 
system, lack of inhibition of these enzymes results in inappropriate 
bradykinin generation and increase of vascular permeability. Inherited 
deficiency of C1-INH is the basis of hereditary angioedema [47].  
 
CD59 also known as MAC-inhibitory protein (MAC-IP), membrane inhibitor 
of reactive lysis (MIRL), or protectin is the key regulator of the terminal 
pathway. CD59 is a cell surface GPI-anchored glycoprotein of 18-25 KDa 
that is heavily glycosylated. 
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CD59 can be found on all circulating blood cells (erythrocytes and 
leukocytes), endothelial cells, fibroblasts, and in most epithelial cells (in 
pancreas, epidermis, bronchi, kidney, and salivary glands, moreover it has 
also been found on sperm. 
CD59 functions by binding to the α-chain of C8 in the C5b-8 complex and 
preventing subsequent binding of C9, and/or by binding to C9 in the C5b-9 
complex and preventing recruitment of additional C9 molecules, it 
therefore blocks the polymerization of C9 and the formation of MAC [48]. 
Inhibition of MAC assembly by CD59 is species-specific, it only occurs if the 
MAC components are from the same species as the target cell. 
This protein also plays a role in signal transduction pathways in the 
activation of T cells.  
Deficiency of CD59 results in paroxysmal nocturnal hemoglobinuria, a rare 
disease characterized by destruction of red blood cells by the complement 
system [49]. 
 
Thrombomodulin (TM) is a transmembrane glycoprotein abundantly 
expressed on the surface of vascular endothelial cells and is mainly 
involved in anticoagulant pathway. TM binds thrombin forming a 1:1 
stoichiometric complex thus sequestering it from its substrates, platelets 
and fibrinogen. Moreover, after the binding, thrombin changes its 
specificity from fibrinogen to protein C activating it. Activated protein C 
makes a complex with protein S and cleaves the activated factors V and 
VIII, inactivating them, thus acting as an antithrombotic factor. 
TM can also act as a complement regulator in two ways: it enhances FI-
mediated inactivation of C3b on the cell surface in the presence of the 
cofactor FH [50], and activates TAFI-mediated inactivation of the 
anaphylatoxins C3a and C5a [51]. 
Protein S has also been shown to participate in complement regulation by 
binding C4BP. Protein S in complex with C4BP loses its cofactor activity for 
protein C but enables C4BP to bind  to negatively charged glycolipids [52]. 
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This interaction thus promotes coagulation while controlling complement 
CP and LP activation. 
 
Vitronectin (Vn, S-protein) and clusterin (Cn, SP-40,40, apolipoprotein J) 
are two soluble regulators of the terminal pathway that block the 
incorporation of MAC into membranes. Vitronectin binds preferentially to 
C5b-7 and interacts with C9 inhibiting its polymerization and preventing 
membrane insertion [53]. Clusterin binds not only to C7 in the complex of 
C5b-7 preventing its insertion into the cell membrane, but it can also bind 
to C8 and to C9, inhibiting the polymerization of C9 [54]. 
Soluble complexes of C5b-9 with vitronectin or clusterin (SC5b-9 complex) 
are normally present in serum during complement activation, thus a 
specific enzyme-linked immunosorbent assay (ELISA) for this complex can 
be used to monitor complement consumption. 
 
Properdin as discussed earlier is a stabilizer of the AP. 
 
Factor I (FI) is an 88 KDa serum glycoprotein predominantly synthesised by 
the liver and is a key regulator of complement activation. FI is a serine 
protease that cleaves C3b and C4b to their inactive forms iC3b and iC4b by 
releasing C3f or C4c fragments to the fluid phase. To exert its proteolityc 
functions FI requires cofactor proteins such as Factor H (FH), C4b-Binding 
Protein (C4BP), Complement Receptor 1 (CR1/CD35) and Membrane 
Cofactor Protein (MCP/CD46) [55]. Cleavage of C3b is mediated by FH, MCP 
or CR1, whereas in the proteolysis of C4b cofactor activity (CA) is 
performed by C4BP, MCP or CR1. These cofactor proteins will be discussed 
in more detail later. 
Inactivating C3b and C4b, FI prevents the formation of the C3 and C5 
convertases of both the AP and the CP,  thus acting as regulator for both 
pathways. Moreover, since the AP comprises a feedback loop mechanism 
  
14 
triggered by C3b deposition on a target, inactivation of C3b by FI regulates 
the pathway also at a different level.  
FI is synthesized as a single chain precursor (pro-I) that undergoes post-
translational glycosylation and proteolytic processing before secretion [56]. 
The mature protein is composed of two polypeptide chains linked by a 
single disulfide bond [57]. The heavy chain (50KDa) comprises an N-
terminal region, an FI membrane attack complex (FIMAC) domain, a CD5 
domain (also known as the scavenger receptor cysteine-rich domain), two 
low-density lipoprotein receptor (LDLr) domains and a C-terminal region of 
unknown function. The light chain (38KDa) contains the serine protease 
(SP) domain with the conserved catalytic residues. 
Inactivation of C3b 
FI is able to hydrolyse both membrane bound and soluble C3b in the 
presence of its cofactors. 
In a first step of hydrolysis, FI produces two cuts in the alpha’ chain of C3b 
generating inactive iC3b and releasing a small peptide of 17 amino acids 
(C3f). This cut is performed using as cofactors FH, MCP or CR1. In the case 
of membrane bound C3b, the inactivated iC3b remains bound to the 
surface. The iC3b is then susceptible to another cleavage by FI that 
generates C3c, which is soluble in plasma, and C3dg, that remains bound to 
the surface if the starting point is membrane bound C3b. This second cut 
occurs only when CR1 is a cofactor [58]. (Fig.4). 
 
Fig. 4 Inactivation of C3b by factor I 
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C3dg can be further cleaved by plasma proteases to C3d that is thought to 
have similar biological activity than C3dg. 
None of these fragments can activate the complement cascade, but the 
hydrolysis products iC3b, C3c and C3dg can bind to specific complement 
receptors and mediate functions such as the clearance of immune 
complexes, opsonization, B cell stimulation and immunological memory. 
Inactivation of C4b 
In the presence of the cofactors C4BP, CR1, or MCP, FI cleaves the 
membrane bound C4b inactivating it to iC4b. After a second cleavage the 
soluble fragment C4c is released and the  residual C4d, with unknown 
biologic activity, remains bound to the membrane. (Fig. 5) 
 
Fig. 5 Inactivation of C4b by factor I 
 
2.2.1. RCA regulators 
RCA regulators are a family of genetically, structurally and functionally 
related proteins. 
They are composed of 4 to 30 homologous short consensus repeat (SCR) 
domains, also known as complement control protein (CCP), that have 
probably arisen by gene duplication events [59]. SCRs are small domains, 
composed of approximately 60 amino acids each, that are characterized by 
a high degree of conservation. They all contain four invariant cysteines that 
form two disulfide bridges essential to maintain a globular bead-like 
structure of the domain [60, 61]. (Fig. 6). The SCR domains are usually 
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arranged in proteins in a head-to-tail fashion making RCA proteins 
resemble beads-in-string [62]. The binding sites in SCR- bearing proteins 
may span over several domains and therefore the orientation between the 
SCRs is critical for the function of the protein. 
 
Fig. 6 Structure of a SCR domain. The SCR domain is composed of around 60aa 
and contains 4 cysteines that form 2 disulfide bridges essential to maintain its 
globular bead-like structure. 
 
Another common feature of these components of the RCA is that their 
regulatory function are closely related. They act mainly on convertases by 
accelerating the dissociation of the C3 and C5 convertases or attending FI 
as cofactors in the proteolytic degradation of C3b and C4b. 
Among RCA regulators we can find both cell membrane-associated and 
fluid phase proteins (Fig.7). Membrane-bound complement regulators 
include membrane cofactor protein (MCP/CD46), decay-accelerating factor 
(DAF/CD55), and complement receptor 1 (CR1/CD35), whereas 
complement receptor 2 (CR2/CD21), is encoded by the same locus, but has 
not been shown to regulate complement. Human cells are protected from 
complement-mediated lysis because they expose these regulators on their 
surface. On the other hand, soluble regulators limit the activation and the 
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consumption of complement in the fluid phase, those include C4 binding 
protein (C4BP), factor H (FH), factor H-like protein 1 (FHL-1), and factor H 
related (FHR) proteins. 
  
Fig. 7 RCA regulatory proteins. Membrane-bound and fluid phase RCA proteins 
are represented. They all are composed by SCR domains indicates as beads. 
MCP (CD46) is a transmembrane glycoprotein widely expressed on cells 
that are in contact with the blood stream such as leukocytes, platelets, 
endothelial cells, epithelial cells and fibroblasts, with the exception that it 
is not present on erythrocytes [63]. It consists of an extracellular part 
formed by 4 SCRs followed by 1-3 serine/threonine-rich (ST) domains, a 
hydrophobic transmembrane domain and a cytoplasmic tail. More than 8 
isoforms can be produced by alternative splicing. 
MCP inhibits complement activation on host cells functioning as a cofactor 
for factor I mediated cleavage of C3b to iC3b and C4b to C4c and C4d, thus 
abolishing the ability of C3b and C4b to form C3/C5 convertases [64]. MCP 
is an “intrinsic regulatory protein” as it can bind to C3b/C4b deposited on 
the same cell membrane but not on other cell membranes, thus protecting 
from complement attack only those cells on which it is expressed. 
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DAF (CD55) is a 70 KDa glycoprotein bound to the cell membrane by a GPI-
anchor followed by a serine/threonine-rich (ST) region and 4 consecutive 
extracellular SCRs. It’s expressed on the surface of all blood cells and in 
various tissues and organs [65]. A soluble isoform generated by alternative 
splicing is present in body fluids [66]. 
DAF can control complement activation at different levels accelerating the 
dissociation of both C3 and C5 convertases. DAF binds to the AP C3 
convertase, C3bBb, accelerating its dissociation and also decreases the 
stability of the CP/LP C3 convertase, C4bC2a, by accelerating its 
dissociation to C4b and C2a [67]. In this way C3b peptides can no longer be 
produced to bind to the surface of the cells. DAF can also bind and 
dissociate C5 convertases on the surface of cells, thus protecting cells from 
lysis mediated by the membrane-attack complex [67]. 
Complement receptor type 1 (CR1) is a large, multifunctional, 
transmembrane glycoprotein. It is composed by a cytoplasmic domain, a 
transmembrane region and a large extracellular domain composed of 30 
SCRs in the most frequent allele. Three other alleles are possible containing 
respectively 27, 37 or 44 SCRs. On the basis of the degree of homology the 
SCRs are further grouped into larger units, called long homologous repeats 
(LHRs) and designated LHR-A, -B, -C, and -D. The number of LHRs in the 
different allelic forms varies from three to six [58].  
CR1 is expressed on all peripheral blood cells with the exception of 
platelets, natural killer cells and most T cells [68] and is also found in 
glomerular podocytes, astrocytes and hyalocytes (vitreal macrophages). 
CR1 binds C3b and C4b, and, with a lower affinity, iC3b and C3dg [58]. 
Different LHRs bind to different substrates and bear different activities. 
CR1 on circulating cells acts mainly as an immune adherence receptor to 
facilitate the removal of C3b/C4b-opsonized immune complexes and 
pathogens from the circulation, which after binding  are transported to 
liver and spleen where they are processed by macrophages [12]. 
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CR1 also exerts complement inhibitory activities: it possesses decay-
accelerating activity (DAA) for both CP and AP C3 and C5 convertases and it 
irreversibly inactivates all four convertases, due to its co-factor activity (CA) 
for factor I-mediated cleavage of C3b and C4b. CR1 is not particularly 
efficient in generating iC3b, but is the only co-factor protein able to carry 
out the third cleavage of C3b to generate C3c which is released to fluid 
phase and C3dg [58].  
CR1 has also been reported to bind to the collagenous portions of C1q [69] 
and to mannan-binding lectin (MBL) [70]. 
Complement receptor 2 (CR2) which is expressed on B-lymphocytes binds 
to iC3b, C3dg, or C3d and has a role in B-cell activation, bridging innate and 
acquired immunity [71], but a specific role in complement regulation has 
not yet been discovered. 
C4 binding protein (C4BP) is a large soluble glycoprotein, present in plasma 
at a concentration of approximately 200 µg/ml. C4BP exists in several 
isoforms, the major form (α7/β1) is composed of seven identical α-chains 
(70 KDa) and a single β-chain (45 KDa) all linked together at the C-termini 
by disulfide bridges in a unique “octopus-like” structure (Fig. 8) [72]. Other 
less abundant forms are composed of six α-chains and one β-chain (α6/β1) 
or exclusively of seven α-chains (α7/β0) or of six α-chains (α6/β0). Both α- 
and β-chains are composed of multiple SCRs domains, the α-chain contains 
eight and the β-chain three. The SCRs domains in both chains are followed 
by a C-terminal extension (~60 amino acid residues long) which contain an 
amphiphatic α-helix region and two cysteines that are required for 
intracellular polymerization and interchain disulfide bridging [73]. 
The genes encoding for both the α-chain (C4BPA) and the β-chain (C4BPB) 
are located in the RCA gene cluster in close proximity. 
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Each of the α-chains contains a binding site for the activated complement 
protein C4b, whereas the β-chain binds to coagulation system protein S 
[74, 75]. 
 
Fig. 8 Structure of C4BP. The major isoform (α7/β1) composed of 7 α-chains and 
1 β-chain is indicated. This protein has a unique “octopus-like” structure. 
C4BP is the main inhibitor of the CP and LP of complement, where it 
controls C4b-mediated reactions in several ways. 
C4BP functions as a cofactor to factor I in the regulation of the complement 
system, with C4b as the primary target. C4b bound to C4BP α-chain is a 
substrate for FI, that cleaves it into inactive C4b (iC4b) [72]. However, C4BP 
can also serve as cofactor to FI in the regulation of the complement protein 
C3b, even though other proteins such as FH, MCP, and CR1 are more 
efficient in supporting C3b degradation.  
Moreover, C4BP prevents the assembly of the classical C3-convertase by 
binding nascent C4b and it also accelerates the natural decay of the 
complex [76]. On the other hand, C4BP does not seem to be an inhibitor of 
the assembled alternative C3-convertase [77].  
The binding of C4BP β-chain with protein S enables the S-C4BP complex to 
bind to negatively charged phospholipid membranes, thus providing C4BP 
with the ability to interact with certain cell surfaces, where it can express 
its complement regulatory activities. 
During the apoptotic process, negatively charged phospholipids, that are 
normally located in the inner part of the cell membranes, are exposed on 
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the surface of the apoptotic cell. The protein S-C4BP complex can bind and 
inhibit the activation of complement on the apoptotic cell, which may be 
important for the controlling the inflammatory process. However, the 
protein S-C4BP complex does not stimulate phagocytosis of the apoptotic 
cells [78]. 
Factor H (FH), factor H-like protein 1 (FHL-1), and factor H related (FHR) 
proteins will be discussed in more detail. 
3. Complement Factor H 
Complement Factor H (FH), the main regulator of AP, was first identified in 
1965 by Nilsson and Müeller-Eberhard as β1H globulin [79]. Factor H is a 
single polypeptide chain plasma glycoprotein of 155 KDa composed of 20 
SCR domains [80]. 
FH is synthesized mainly by the liver [81], but extra-hepatic synthesis has 
been demonstrated in a variety of tissues including endothelial and 
epithelial membranes, glomerular mesangial cells, platelets, mesenchymal 
stem cells and retinal pigment epithelium [82–86]. 
FH plasma levels in humans is very variable (116-562 μg/ml) and it has 
been shown to be influenced by environmental factors such as age and 
smoke, although the genetic component accounts for the major part 
(~62%) [87]. 
3.1. FH functions 
The main function of FH is down-regulation of AP which is achieved in 
three different ways: FH competes with FB for binding to C3b, thus 
preventing formation of C3 and C5 convertases of the AP [88]; FH also 
possesses decay acceleration activity (DAA) and promotes the dissociation 
of these convertases once they have formed [89]; finally it acts as an 
essential cofactor for FI in the proteolytic conversion of C3b to iC3b [90]. In 
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the absence of FH, spontaneous activation of AP occurs in plasma and 
leads to consumption of complement components C3 and FB [22]. 
The regulatory function of FH, which is mainly due to its interaction with 
C3b, is performed both in the fluid phase and on self-surfaces where C3b is 
bound. However, while FH binds and inactivates C3b promptly in fluid 
phase, the inactivation of surface-bound C3b by factor H is dependent on 
the chemical composition of the surface. 
FH is able to distinguish between self and foreign surfaces and this is 
mainly due to its capacity to bind polyanions such as sialic acid and 
glycosaminoglycans (GAGs) such as heparin. The presence of these markers 
on self surfaces increases the affinity of FH for surface-bound C3b as a 
consequence of the simultaneous recognition of both types of molecules 
by the same FH molecule [91–93]. Thus, FH acts by selectively limiting the 
progression of the complement cascade on the surfaces of self-tissues and 
allowing amplification of the AP only on foreign surfaces. 
3.2. FH structure and functional domains 
FH mature protein is composed of 1213 amino acid residues that are 
organized in 20 SCRs of ~60 residues each joined in a “string-of-beads” 
arrangement by 19 linkers of 3-8 residues. 
A multiple alignment of the 20 SCRs highlights four invariant Cys residues 
and a near-invariant Trp residue between Cys(III) and (IV). This consensus 
sequence also occurs multiple times in other members of the RCA family. 
Each of the 20 SCRs is presumed to fold into a distinct three-dimensional 
(3D) structure termed the complement control protein module (CCP) 
stabilized by two disulphide bounds between Cys(I)-(III) and Cys(II)–(IV) 
[94]. 
Different parts of the protein contain binding sites for different ligands. 
(Fig. 9). Functional and interaction assays using the whole molecule or 
recombinant fragments enabled to establish a protein map characterizing 
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the binding sites for C3b and polyanions [95–102]. FH contains three 
regions important for binding C3b; two main binding sites located at each 
end of the molecule and a third one in the central part of FH. The binding 
site present in the N-terminal part (SCRs 1-4) is the only one necessary and 
sufficient to perform the cofactor function for FI. It also accelerates the 
dissociation of the convertase, although other regions of FH must 
contribute, as the dissociation capacity of the fragment FH-SCRs 1-4 is 100 
times lower than that of the whole FH [100]. The binding site for C3b 
localised in the C-terminal region (SCRs 19-20) has the highest affinity to 
C3b, however, both sites at opposite ends must cooperate in binding to 
C3b. SPR interaction assays demonstrate that affinity of the entire FH is 
much higher than that of the N- and C-terminal fragments taken separately 
[103]. Moreover, SPR interaction assays also demonstrated that the three 
different binding sites on FH interact with distinct sites on C3b [99], and 
they can also bind C3b degradation fragments. The C3d fragment of C3b 
binds to SCRs 19-20 whereas the central binding site is specific for C3c. 
The interaction of FH with GAGs and polyanions has been located mainly to 
two regions: SCR 7 with the contribution of SCRs 6 and 8, and SCRs 19-20, 
in which SCR20 is the main heparin-binding site [103]. Another central 
binding site (SCRs 12-15) has been proposed but never been confirmed. 
These sites enable the binding of FH to host cell surfaces, but not to the 
surfaces of pathogens, thus leading to the complement regulatory 
protection of host cells. 
FH also binds C-reactive protein (CRP) at SCR 6-8 and SCR 16-20 [104]. CRP 
bound to damaged host cells can bind FH leading to C3b regulation. 
Weak zinc binding sites are primarily located within SCR 6-8; these sites 
lead to the precipitation of FH–C3b complexes in the pathophysiological 
concentrations of zinc found in the retina [105]. In addition to these ligand 
interactions, FH self-associates with itself to form dimers and higher 
oligomers [106]. 
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Fig. 9 Structure of FH. FH is composed of 60 SCR domains. Binding sites for 
different ligands are indicated. 
The structure of FH, composed by 20 SCRs linked by short sequences, 
unlike it was previously believed, is not completely flexible, however N and 
C-termini are brought close to each other (Fig. 10). This architecture must 
be functionally relevant to allow both ends of FH to interact with the same 
molecule of C3b. This would explain how C3b binding sites, SCRs 1-4 and 
SCRs 19-20, cooperate and confer avidity. Several models of FH-C3b-
Heparin interaction have been proposed. Morgan HP et al hypothesised a 
model of FH-C3b in which a single molecule of FH interacts with one of C3b 
in non-overlapping regions through binding sites located at opposite ends 
of FH (FHSCR1-4-C3b and FHSCR19-20-C3d/TED), and further enables the C-
terminal region of FH (SCRs 19-20) to bind to polyanions on the surface 
[107]. 
 
Fig. 10 FH-C3b-heparin complex. FH is a rigid structure but can fold in on itself, 
bringing the two ends close to each other and enabling interaction with C3b and 
polyanions. 
  
25 
The highly complex FH structure can be essentially divided into two 
functional regions: 
- The N-terminal region, which binds to C3b and bears the regulatory 
activities, such as cofactor activity (CA) and decay acceleration activity 
(DAA) 
- The C-terminal region, which binds to C3b and polyanions and provides 
the selective ability to interact with surfaces 
The correct activity of FH depends on cooperation between these two 
regions and with the other interaction sites. 
3.3. The CFH gene 
FH is encoded by a single gene (CFH), located within the RCA in the region 
1q32. The CFH gene contains 23 exons, the first exon codes for the 5'UTR 
and signal peptide. Each of the other 22 exons code for one of the 20 SCR 
domains except SCR 2 which is encoded by exons 3 and 4 (Fig. 11).[5] 
 
Fig. 11 Structure of the CFH gene. Structure of CFH gene and different exons 
coding for the two isoforms FH (white boxes) and FHL-1 (black boxes) are 
indicated. Location of the CFH gene in the RCA cluster, in close proximity to 
CFHRs genes, is also indicated. 
From the same gene an alternative transcript is produced that codes for a 
43 KDa protein named FH-like 1 (FHL-1). FHL-1 shares with FH the first 9 
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exons, which code for the first seven SCRs, plus exon 10, which is absent in 
the mature messenger coding for FH. Exon 10 possesses a premature stop 
codon and codes for a short tail of four amino acids (Ser Phe-Thr-Leu) 
[108]. Both proteins are mainly expressed by the liver, but the plasma 
concentration of FHL-1 is much lower (10-50 µg/ml). FHL-1 has 
complement regulatory functions, such as cofactor activity for FI and 
convertase C3bBb dissociation activity. FHL-1 is also capable of binding to 
heparin, various microbial proteins, and cell surfaces, being involved in cell 
motility processes [100, 109].  
Despite FH and FHL-1 share the promoter region and the transcription start 
site, the regulation of their expression is different depending on the 
cellular type. The reason for this difference is unknown but it probably 
depends on different transcriptional and post-transcriptional mechanisms 
[110]. This suggests that there are specific functions for FH and FHL-1, 
where both the tissue and the local concentration can be very important. 
However, the precise role of FHL-1 in vivo is not determined. 
3.4. Factor H protein family 
In the RCA cluster, just downstream of the CFH gene, we can find five 
genes (CFHR1, CFHR2, CFHR3, CFHR4, CFHR5) coding for the FH-related 
proteins (FHRs) (Fig. 10). These proteins, together with FH and FHL-1 form 
a family of glycoproteins (“Factor H protein family”) which are structurally 
and functionally related [111]. 
The chromosomal segment containing CFH and CFHR genes is 
characterized by several large genomic repeat regions, including different 
exons of CFH and CFHRs 1-5, which have a high degree of sequence 
identity. This situation favours non-homologous recombination processes 
that result in chromosomal rearrangements and can lead to both deletions 
and duplications. Chromosomal rearrangements can result in the loss of a 
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single or several CFHR genes, but can also give rise to new gene-
compositions and hybrid genes including in some cases also the CFH gene. 
Rearrangements within the FH gene family may lead to defects associated 
with pathology [5, 112]. 
The FHRs 1-5, as FH, are composed exclusively of SCRs and contain from 4 
to 9 domains. They possess two conserved regions: the N-terminal one, 
corresponding to the central region of FH (SCRs 6-9) with which it shows a 
high degree of sequence identity (36–94%) and the C-terminal one, which 
is very similar to the FH C-terminus (SCRs 19-20) (36–100% identity) (Fig. 
12). 
 
Fig. 12 Schematic representation of FH and FHRs. Similarity between SCRs of 
FH and FHRs is indicated and represented by different shades of blue. 
The sequence similarity and the presence of conserved domains suggest 
that these proteins possess related and even shared functions. The 
conservation of the C-terminal region of the FHRs suggests that these 
proteins, similarly to FH, can bind to surface ligands and discriminate 
between self and non-self tissues. All five FHR proteins have been shown to 
  
28 
bind to C3b and to C3d. Of the two C-terminal SCRs in FHR proteins, the 
one that corresponds to SCR19 in FH is highly conserved whereas the one 
corresponding to SCR20 is more diverse. SCR20 of FH harbours an 
important heparin binding site, suggesting that the FHRs may recognize 
and bind to different cell surfaces. 
On the other hand, the lack of a regulatory region such as the one present 
in SCRs 1-4 of FH, with cofactor and decay activity, implies that FHRs are 
not very potent in regulating complement [111]. 
According to their conserved domains, FHR proteins are divided into two 
major groups: group I includes FHR-1, FHR-2 and FHR-5 whereas group II is 
composed by FHR-3 and FHR-4 [113]. 
Proteins in group I are composed of a different number of SCR domains: 
FHR-1 has five, FHR-2 four SCRs and FHR5 nine. This group is characterized 
by their conserved N-termini (SCR1 and SCR2) which have more than 80% 
sequence identity. These proteins circulate in plasma exclusively as dimers 
(homodimers or heterodimers), and their dimerization is mediated by the 
two conserved N-terminal SCRs. 
FHR-1 is composed of five short SCRs, it possesses a dimerization domain in 
the N-terminus and forms homodimers and likely also heterodimers with 
FHR-2 and FHR-5. 
Two variants of FHR-1 have been identified, an acidic isoform (FHRA) that 
expresses the amino acids HLE in SCR3 and a basic isoform (FHRB) 
expressing YVQ in SCR3. FHR-1 circulates in human plasma in two 
glycosylated forms: FHR-1α with one and FHR-1β with two carbohydrate 
side chains. The plasma concentration of CFHR1 is about 70 to 100 μg/ml. 
FHR-2 consists of four SCRs, it forms homodimers and likely also 
heterodimers with FHR-1 but not with FHR-5. The protein has two 
glycosylated forms, a single glycosylated (24 KDa) and a double 
glycosylated form (28 KDa). The plasma concentration is estimated to be 
about 1/10 of FH, around 50 μg/ml. 
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FHR-5 is composed of nine SCRs and is the longest FHR protein, it circulates 
in the plasma as homodimer and likely also as a heterodimer with FHR-1. 
FHR-5 is the only FHR protein that has five SCR domains with high sequence 
identities to SCRs 10–14 of FH. FHR-5 is a glycosylated protein of 62 KDa. 
The group II FHR proteins, as well as factor H, lack the N-terminal 
dimerization domains. FHR-3 and FHR-4 show a high degree of amino acid 
identity to the SCRs 6–8 of FH (63 to 95%). SCRs 6–8 of factor H mediates 
binding to heparin and to monomeric C-reactive protein (CRP), which is 
conserved in FHR-4 [111]. 
FHR-3 consists of five SCR domains that show high amino acid identity to 
SCRs 6-7-8 and SCRs 19-20 of FH. It is detected in plasma in multiple 
variants (ranging from 35 to 56 KDa), reflecting the existence of four 
different glycosylated variants of FHR-3. The plasma concentration is 
estimated to be similar to FHR-1 (70–100 μg/ml). 
FHR-4 is composed of nine SCRs and appears with an internal duplication 
similar to an internal dimer, as SCRs 1–4 show a high level of identity to 
SCRs 5–8 of the same protein. As FHR-3, it also has sequence identity to FH 
SCRs 6-7-8 and SCRs 19-20. The human CFHR4 gene codes for two proteins, 
FHR-4A and FHR-4B. FHR-4B derives from an alternatively spliced transcript 
of the CFHR4 gene and is composed of five SCRs that correspond to half of 
the SCRs of FHR-4A, in detail SCR1 and SCRs 5–9. FHR-4B has a mobility of 
42 KDa and FHR-4A of 86 KDa. The plasma concentration of the two 
variants has not yet been determined.  
The high amino acid identity among the family members is also reflected 
by the fact that antibodies raised against FH also detect different FHRs in 
plasma and that the antibodies generated against FHRs cross-react with 
other FHRs. Moreover, auto-antibodies against factor H in aHUS recognize 
not only factor H but also certain FHRs [114]. This cross-reactivity is a 
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challenge for FHRs purification from plasma, their concentration 
determination and in depth analysis. 
The exact function of FHRs is still uncertain, but the functional relationship 
between them and FH is now clearer: they can cooperate with FH in the 
regulation of complement activation or compete for binding to ligands and 
surfaces, which would result in less regulation. 
4. Factor H-Associated Diseases  
Complement activation and its regulatory mechanisms are in strict balance, 
such that the effector activities of complement are normally directed 
towards foreign surfaces and are avoided against self ones. Any imbalance 
can lead to tissue damage, susceptibility to infection, as well as chronic 
pathology.  
Complement regulatory defects due to FH mutations or anti-FH 
autoantibodies have been described in certain pathological conditions, and 
CFH polymorphisms have also been associated with disease. 
Among FH-associated diseases, the best studied are atypical Hemolytic 
Uremic Syndrome (aHUS), Dense Deposit Disease (DDD) which affect 
primarily the kidney with predominant glomerular dysfunction and Age-
related Macular Degeneration (AMD), a late onset eye dysfunction causing 
impairment of the central vision. aHUS and AMD well be discussed in more 
detail here. 
4.1. Atypical Hemolytic Uremic Syndrome 
The Hemolytic Uremic Syndrome (HUS) is a microvascular dysfunction 
mainly affecting the kidney, but also the gastrointestinal and central 
nervous systems can be involved. This condition is clinically defined as 
hemolytic angiopathic anemia, thrombocytopenia and acute renal failure.  
The main events triggering the pathogenic process seem to be endothelial 
lesions in glomerular microvasculature due to either infection or other 
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exogenous damaging causes. These lesions show thickening of arterial and 
capillary walls, endothelial inflammation and detachment of the glomerular 
basal membrane (GBM), in addition to sub-endothelial accumulation of 
proteins and cellular debris as well as formation of microclumps of 
platelets and fibrin which may cause vascular occlusion. Generation of 
schistocysts (fragmented erythrocytes) due to the circulation through 
partially occluded renal microvasculature is another feature of HUS [115]. 
Two types of HUS are traditionally distinguished. The most frequent form 
(90% of the observed cases), called typical, mainly affects children and has 
an incidence of 2 cases per year every 100.000 inhabitants. Typical HUS is 
associated with infection by an entero-haemorrhagic strain of Escherichia 
coli (0157:H), which produces a highly toxic Shiga-like toxin. Although the 
mechanism of action of this toxin has not yet been totally clarified, its role 
in causing haemorrhagic diarrhoea and the evolution of this disease is not 
under dispute. After crossing the intestinal barrier and entering the 
systemic circulation, the Shiga toxins bind to receptors on the endothelial 
surface causing lesions and triggering an inflammatory status and pro-
thrombotic episodes. Most cases of typical HUS have a positive outcome 
and kidney function is restored in at least 75% of the patients. The 
remaining cases can develop chronic kidney disease and in some cases 
might even die (3-5%). [115]. 
Approximately 10% of cases of the hemolytic–uremic syndrome are 
classified as atypical HUS (aHUS), since they are not caused by either Stx-
producing bacteria or streptococci. Atypical HUS can affect both children 
and adults, its incidence corresponds to two cases per year per 1.000.000 
inhabitants. Based on histological findings, the lesions observed in aHUS 
are indistinguishable from those of the typical form; however, aHUS has a 
much worst prognosis. Most patients show recurrent episodes and half of 
them develop chronic kidney disease (CKD). aHUS mortality is 
approximately 25%  [116]. 
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No special association has been found for aHUS, but a number of risk 
factors have been found which predispose to this disease. Among them, 
immune suppressing or anti-cancer therapies, oral contraceptives, 
pregnancy and post-partum. 
On the other hand, several studies have found, in familiar cases of aHUS, 
and less frequently in sporadic cases, a clear genetic component. In some 
cases of aHUS, mutations were found in genes coding for pro-coagulant 
proteins, such as Thrombomodulin (TM), most patients were found 
carrying mutations on genes coding for the alternative pathway of 
complement (AP) [117]. 
The involvement of complement in HUS is known since 1974, but only in 
recent years a clear association between aHUS and specific complement 
proteins has been assessed. In many instances aHUS-associated mutations 
and polymorphisms have been identified in regulatory proteins such as FH, 
MCP, or FI and more recently to components FB and C3 [117]. In most of 
these mutations functional defects have been identified which affect up to 
half the aHUS cases. This implies that complement AP is somehow directly 
involved in the pathogenesis of this disease.  
In spite of all this evidence, in most cases a specific genetic or 
environmental cause which might be considered the triggering event has 
not been found. This calls for the existence of additional factors that have 
not yet been identified. Among the mutations that have been described, 
most are located in the CFH gene, which deserves special attention in the 
pathogenesis of this disease [118].  
4.1.1. FH in aHUS 
Factor H mutations affect approximately 30% of aHUS patients, more than 
100 mutations have already been described. An updated record of all 
mutations associated with aHUS can be found at the FH–HUS online 
database (http://www.fh-hus.org) [119]. 
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Heterozygous mutations affecting various domains of FH have been 
associated with aHUS,  however missense mutations in the C-terminal 
region (SCRs 19-20) are the most prevalent genetic alterations among aHUS 
patients. Furthermore, in a significant number of patients mutations 
affecting the functionality of the C-terminal region are the result of gene 
conversion events between exon 23 of CFH and the homologous exon 6 of 
CFHR1 [120] or of genomic rearrangements creating CFH::CFHR1 hybrid 
genes [121]. 
FH mutations associated with aHUS rarely result in decreased FH plasma 
levels, the majority of mutant proteins express normally and present 
normal co-factor activity for the FI-mediated proteolytic inactivation of C3b 
in plasma [122]. Functional analyses of several of these mutants showed an 
altered interaction with C3b, heparin and endothelial cells [122–124]. 
As mentioned above, aHUS-associated FH mutations cluster in the C-
terminus of the protein, a region that is critical to control activation of 
complement on cell surfaces. Consistent with this location, carriers of these 
mutations express FH molecules that present normal regulatory activity in 
plasma but a limited capacity to protect self cells from complement attack 
[125]. 
Recent structural studies have provided new insights into how these 
mutations impair the function of factor H in host/non-host discrimination 
[107, 126]. Certain mutations in SCR20 were also found to reduce the 
binding of FH to CRP [127] and to PTX3 [114]. For many mutations, 
however, there is no functional effect known to date. 
Moreover, anti-FH autoantibodies are detected in approximately 10% of 
aHUS patients, mostly children. These antibodies have functional 
consequences similar to those caused by the mutations in the C-terminal 
region of FH [128, 129]. 
Several studies using recombinant FH fragments have been performed to 
determine the binding sites of these autoantibodies and have shown that 
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they bind mainly to SCRs 19-20, although in some cases reactivity with 
other domains, such as SCRs 8-11, was also observed [130]. 
Functional studies indicated that the autoantibodies directed against SCRs 
19-20 interfere with the FH recognition functions impairing its interaction 
with surface-bound C3b and thus inhibiting its complement regulatory 
activity on host surfaces [130]. This reduced protection from complement-
mediated damage is likely to be involved in the endothelial injury 
associated with aHUS. 
Interestingly, 90% of the affected individuals presenting anti-FH antibodies 
are also homozygous for the deletion of the CFHR1 and CFHR3 genes, it’s 
still unclear whether the deletion of these genes predisposes to the 
development of FH autoantibodies or if they are independent risk factors 
for aHUS [129, 131, 132]. What is certain is that, due to the similar C-
terminal SCRs of FH and FHR-1, most of the studied autoantibodies 
recognize both host complement regulators. FHR-1 in fact can hijack 
autoantibodies and rescue host cells when added to anti-factor H 
autoantibody-positive plasma [133]. 
A mouse model of aHUS is available, in which a truncated form of FH 
(FHΔ16-20) that lacks the terminal five SCR domains, equivalent to the 
location of the majority of aHUS-associated FH human mutations, is 
produced [134]. 
4.2. Age-Related Macular Degeneration 
AMD is the main cause of elder blindness in the industrialized countries. It 
is an eye lesion affecting the central part of the retina, also known as 
macula. AMD diagnosis is based on the degeneration signs that are evident 
in the macula, independently from vision sharpness. Although substantial 
histological changes are associated with AMD in the retina retinal pigment 
epithelium (RPE), choriorcapillaris and choroid in middle age, AMD does 
not manifest clinically before 55 years of age [135]. 
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The typical clinical sign of AMD are the drusen, the origin of which is still 
today totally unknown. As seen through the ophthalmoscope, they appear 
as white to yellow dots in the retina, sometimes with a crystalline and 
shiny aspect. They are extracellular deposits that accumulate between the 
RPE basal membrane and the inner collagen layer of the Bruch membrane 
[135]. 
The drusen are found in different eye diseases, and constitute a relevant 
risk factor for the development of AMD. This association is very strong, and 
as a consequence the presence of drusen is considered as a sign of an 
early-stage of AMD, even in the absence of vision loss. Both the size and 
the number of drusen are related to AMD severity. Drusen composition is 
variable and not well defined, and only some of its components are known. 
Their inside mainly contains glycoproteins and phospholipids, and in their 
outer layer several proteins have been identified: fibronectin, chaperones, 
apolipoprotein E, vitronectin, Amyloid P and complement proteins such as 
C1q, C4, C5, C3 (and its degradation fragments), as well as the C5b-9 
complex. The have also been shown to contain RPE cellular debris [136]. 
There is an early, almost asymptomatic stage in AMD, which is 
characterised by the appearance of drusen as well as mild changes in RPE 
pigmentation. In the later stage there is a severe vision loss, and the 
disease may be classified as non-exsudative “dry”, or atrophic and 
exsudative “wet” or neovascular. In the former case, well-defined 
hypopigmented regions are produced, something known as “geographic 
atropohy”, and the typical symptoms are blind holes or spots of vision. The 
most advances stage is characterised by the presence of serum or 
hemorrhagic fluid in the extracellular space, which causes the detachment 
of the neuro-retina or of the RPE.  
A typical sign is the choroidal neovascularisation, which can diffuse through 
the Bruch membrane until towards the RPE. These changes generate 
distorted images, which is often a sign of the wet form of AMD. Both types 
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of AMD can coexist in the same patient, and one type can change into the 
other. The general progression is from the dry to the wet form: from 10 to 
15% of patients evolve from the dry to the wet form [135]. 
The RPE is the main component of the retina which is involved in the 
pathogenesis of AMD. The drusen structurally and functionally modify the 
RPE, induce thickening of the monolayer, removing it from the intimate 
vascular support of the choroidal region. This causes the interruption of 
nutrient and metabolite supply and disposal of waste between the retina 
and the choroid capillaries. Moreover, the modifications of the Bruch 
membrane cause the impairment of cell adhesion, a reduced regenerative 
capacity of the neuroretina by the RPE cells. All this, together with the 
effect of neovascularisation, has a deep impact on the photoreceptors with 
a direct negative effect on central vision. The extracellular deposits and 
some of the components present in the drusen, such as activated 
complement proteins and complement regulators, in addition unchain the 
local inflammatory reactions that are involved in the pathogenesis of AMD 
[135]. Changes in these eye structures, such as thickening of walls and loss 
of permeability are naturally occurring as an aging feature. However, the 
influence of environmental and genetic factors is very important. 
AMD is a late onset complex disease caused, like many other multifactorial 
diseases, by the convergent action of multiple risk factors. Among these, 
we can quote aging, cigarette smoke, a high body mass index, and 
especially genetics [135]. Multiple genes appear to be associated with 
AMD, and particularly of note are Fib15, ABCA4, ApoE, HTRA1, ARMS2 and 
different complement genes: CFH, CFB, C2, C3 and CFI [137]. 
HTRA1 and ARMS2 are on locus 10q26 and are strongly associated with 
AMD. The former codes for a serine protease localised in the retina (as well 
as in other tissues) and the latter is a hypothetical gene with unknown 
function. An ARMS2 haplotype has been described with a sequence change 
(Ala69Ser) which increases the risk of AMD up to 6.3 times in homozygous 
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carriers. However, the existence of this theoretical protein has not been 
confirmed and its correlation with AMD pathogenesis is still elusive [137]. 
The most significative genetic association with AMD was found with the 
locus 1q32, where the CFH gene is found. 
4.2.1. FH in AMD 
The common FH polymorphism Tyr402His has been associated with AMD 
and the 402H variant represents the higher risk factor for developing the 
disease. This association has been confirmed in different human 
populations with an Odds Rate between 2.45 and 4.6 in heterozygous 
subjects and up to 7.4 in homozygotes [138–140]. The frequency of the 
402H varies among different populations, which explains the differences in 
the incidence of this polymorphism for AMD.  
Functional studies revealed different binding properties of the of the two 
FH variants (402Y and 402H). The 402H variant has a reduced binding 
affinity to CRP and a higher affinity for DNA and necrotic cells compared to 
the 402Y variant. Since residue 402 is situated in SCR7 which is involved in 
binding to the GAGs, there are also subtle differences between the variants 
in their interaction with heparin and GAGs [141, 142]. 
No difference in binding to retinal pigment epithelial cells was found, but 
the disease-associated variant binds less efficiently to both the 
extracellular matrix protein fibromodulin and the Bruch’s membrane in the 
retina [143]. 
Additional SNPs in the CFH gene associated with AMD were identified. 
A polymorphism in exon 2, resulting in a Isoleucin to Valine exchange at 
amino acid position 62 (I62V) of FH and FHL-1 has been reported. The 62I 
variant is associated with the protective form for AMD and most likely has 
a higher thermal stability [144].  
The protective 62I variant has been shown to possess an increased affinity 
for C3b and enhanced cofactor activity for the FI-mediated cleavage of C3b 
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[145], even though, as shown by crystallographic studies, residue 62 is 
positioned outside the interaction interface of FH with C3b.  
Recently, a new rare polymorphism (R1210C) was described in which the C 
allele confers a 20-fold higher risk of AMD and appears to be involved in a 
significantly earlier onset of the disease [146]. The same polymorphism 
was previously shown to be involved in atypical Hemolytic Uremic 
Syndrome [147]. 
In addition, a protective haplotype associated with the deletion of a 84-kbp 
fragment directly downstream of CFH gene, that includes CFHR1 and 
CFHR3 genes has been described [148]. 
4.3. Interaction with Pathogens 
Since complement plays an important role in protection against infections, 
and is generally regarded as the first line of defence against pathogenic 
microorganisms it is not surprising that numerous pathogens (viruses, 
bacteria, fungi and parasites) have evolved strategies for attenuating or 
escaping complement attack. 
Their mechanisms of action can be condensed to a few successful 
strategies: the recruitment or mimicking of complement regulators; the 
modulation or inhibition of complement proteins by direct interactions; 
and inactivation by enzymatic degradation. 
By acquiring complement regulators onto their surfaces microorganisms 
gain the ability to regulate and control complement activation and can 
evade the destructive effects of this powerful defense system. Many 
pathogens are able to sequester FH on their surface in order to camouflage 
themselves as host-like cells and thus are protected from complement 
attack.  
Binding of FH down regulates opsonization and lead to a rapid inactivation 
of the newly formed C3b at the microbial surface, thus preventing further 
amplification of the complement cascade and the formation of MAC. While 
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prevention of opsonization and subsequent phagocytosis is beneficial for 
practically all microbes, evasion of MAC formation is especially important 
for Gram-negative bacteria and spirochetes. Acquisition of FH is important 
or even essential for pathogens; increasing numbers of them have been 
shown to bind FH [149]. 
There are two main interaction sites on FH for microbial binding: one is 
within SCRs 6–7 and the other in the C-terminal SCRs 19–20. 
Microbes such as group A streptococci [150] and Neisseria [151] have been 
shown to bind to the first site, for example the FH binding protein (FHbp) 
of Neisseria meningitidis binds to SCR6 [152]. 
Binding via SCRs 6–7 facilitates also utilization of FHL-1, which contains 
SCRs 1–7 of FH. Many microbes have been shown to bind both FH and FHL-
1 [153]. 
The mechanisms of interaction with FH/FHL-1 and complement protection 
have been studied in more detail with the Gram-positive bacterium 
Streptococcus pyogenes. Both FH and FHL-1 bind to the streptococcal M5 
and M6 proteins, and under physiological conditions a preferential binding 
of FHL-1 has been observed. In an M-protein bound conformation FHL-1 
retains its cofactor activity and by promoting C3b degradation it can 
contribute to resistance against phagocytosis. The sites required for the 
interaction of the two proteins have been mapped: the surface-exposed 
hypervariable region of the streptococcal M protein interacts with the C-
terminal SCR7 of the FHL-1 protein. Probably the M protein has an 
additional binding site for FH, but despite all the studies no other sites have 
been identified so far. 
However, it seems that the majority of microbes utilize both sites to bind 
to FH: for instance, B. burgdorferi sensu stricto, which causes Lyme disease, 
binds to FH SCR7 using protein CRASP-1 [154] and to SCRs 19–20 using 
outer surface protein E (OspE) and its paralogs [155]. This ability for dual 
binding facilitates efficient protection against the AP attack. 
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Due to the high homology between the C-terminus of FH and C-termini of 
FH-related proteins (FHRs), some microbes bind also certain FHRs but the 
significance of this phenomenon for immune evasion is not yet clear. 
The binding site in the C-terminal was analysed in more detail in a study 
comparing Gram-negative, Gram-positive, and eukaryote microbes known 
to bind FH, and using three microbial proteins, OspE (from B. burgdorferi 
sensu stricto), FhbA (from B. hermsii), and Tuf (from P. aeruginosa). All the 
pathogens and the proteins analysed share a common binding site in SCR 
20 that overlaps but is not identical with the heparin and cellular binding 
sites [156].  
Interestingly, recent studies indicate that the FH 402H polymorphism may 
relate to a better resistance from certain bacterial infections. Haapasalo et 
al. showed that the AMD-associated factor H 402H variant has a lower 
binding affinity to various streptococci compared to the 402Y variant, 
resulting in a more efficient opsonization and phagocytosis [157, 158]. 
These data point to a pathogen-driven establishment of this common 
polymorphism in the human population, with evolutionary advantage 
against bacterial infection at the expense of late-age adverse effects in 
developing AMD. This example raises the possibility that other factor H 
polymorphisms have similarly spread in the human population because of 
the evolutionary race between humans and their pathogens.  
Moreover, interaction of FH with HIV has been previously described by our 
group [159–161]. Envelope glycoproteins gp41 and gp120 have been 
shown to bind to FH and target regions on these proteins have been 
characterized, a possible biding region in FH has been identified in SCR13 
but a full characterisation is still needed. 
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AIM OF THE WORK  
Quantification of FH serum levels and assessment of its functionality are 
crucial for patients characterisation in all FH-associated diseases but, due 
to the high degree of sequence similarity between FHR proteins and FH, 
tests specific only for FH are difficult to develop. Currently available 
methods for the quantification of serum FH are often not specific as they 
recognise both FH and FHR proteins, thus leading to an overestimation of 
real FH levels. Assays for the structural and functional characterisation of 
FH from individual subjects are available, but are usually cumbersome or 
time-consuming and require complex purification procedures [162].  
Many methods for the purification of FH have been reported, these are 
mainly based on multiple chromatography steps needed to obtain a pure 
fraction with minor contamination from FHRs proteins, but they require 
long time and often lead to a partial degradation of FH. 
FH has been shown to interact with several pathogens, but whereas for 
some of them interaction with FH has been well described, for others the 
direct “interactors” still remain unknown. Interaction of FH with HIV has 
been previously reported by our group [159, 160] but up to the present 
only target regions on HIV envelope glycoproteins have been characterized 
whereas an analysis of the binding domains on FH is still needed. 
The present work had a dual purpose with the common aim to better 
understand the role of FH in different pathologies. 
The first aim of my project was to develop FH-specific assays, using a 
monoclonal antibody (MAb 5H5) produced in our laboratory [160]. The 
antibody was first characterised and its ability to recognise specifically FH 
without any cross-reaction with FHR proteins was verified. The antibody 
was then used to purify large amounts of highly purified FH and to set up a 
group of FH-specific assays. 
Two tests respectively for the specific quantification of FH in patients’ sera 
and for the analysis of its structural integrity were first developed and used 
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to screen aHUS and AMD patients. Later two functional assays to assess 
both the N-terminal and C-terminal activity of FH have been set up and 
used to test different samples. 
The second purpose was the cloning and expression of the entire FH or 
partial fragments in both an eukaryotic and a prokaryotic system, in order 
to produce glycosylated and unglycosylated FH.  
The recombinant proteins will be useful for different purposes. First of all 
they can be used to screen which parts of FH are involved in interaction 
with proteins of known pathogens and to explore interaction with other 
pathogens, and also to test the importance of glycosylation in these 
interactions. Secondly, their ability to restore the function of a defective FH 
or to protect against FH autoantibodies can be analysed, with the final goal 
to use them for therapy in many diseases caused by FH defects for which 
the only possible treatment is currently plasma exchange. 
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MATERIALS AND METHODS 
5. Production of 5H5 Monoclonal antibody 
5.1. Suspension cell culture 
A murine hybridoma (5H5) producing a monoclonal antibody (MAb) against 
human FH was thawed and cultivated in T25 flasks with RPMI1640 medium 
(Euroclone) containing 20% Fetal Bovine serum (FBS, Euroclone), 1x 
PenStrep (Euroclone) and 4 mM L-glutamine (Euroclone) in a humidified 
37°C, 5% CO2 incubator. Subsequently cells were subcloned and 
maintained in T75 flasks in RPMI1640 complete medium with FBS reduced 
to 10%. Aliquots were periodically harvested by centrifugation, frozen in 1 
ml FBS aliquots containing 10% (v/v) DMSO (Sigma) and stored at -135°C. 
Production of MAb was periodically checked by a home-made ELISA on 
supernatants. 
5.2. High density cell culture 
In order to enhance antibody production the CELLine Bioreactor (CL1000) 
(INTEGRA Bioscience) has been used. This system permits to cultivate cells 
at high densities (up to 10
7
-10
8
 cells/ml) for a long periods allowing for a 
high production of antibodies, 50-100 times higher than in static culture. 
The bioreactor is a flask with two compartments, a cell compartment and a 
medium compartment, divided by a 10 KDa semipermeable membrane. 
This membrane allows small molecules, as nutrients and waste products, to 
diffuse from one compartment to the other, whereas higher molecular 
weight molecules secreted by the proliferating cells are retained within the 
cell compartment. 
The medium compartment was filled with 1 L of RPMI1640 medium 
containing 1x PenStrep and 4 mM L-glutamine which was completely 
changed every 14 days. 2.5x10
7
 hybridoma cells were collected by 
centrifugation from static suspension cultures, resuspended in 15 ml 
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RPMI1640 medium containing 10% FBS, 1x PenStrep and 4 mM L-glutamine 
and seeded in the cell compartment. Every 7 days all liquid was collected 
from the cell compartment, cells were splitted 1:5 into fresh medium and 
reseeded into the same chamber. The supernatant was checked for the 
presence of antibody by ELISA test before storing it for subsequent 
antibody purification. 
5.3. Purification of 5H5 antibody  
A ProteinG-Agarose column was prepared in order to purify 5H5 
monoclonal antibody from both static or high density culture supernatant. 
1 g of Protein G-Agarose resin (Sigma P7700) was rehydrated in 25 ml of 
deionized water in agitation for 30 min. The resin was then thoroughly 
washed on a Büchner funnel with gentle vacuum using 50 ml of deionized 
water in order to remove the lactose stabilizer. The washed resin was then 
resuspended in PBS buffer and packed into the column. 
For antibody purification the ProteinG-Agarose column was attached to the 
Econo-System (Bio-Rad). Column was washed at 2 ml/min rate first with 
PBS for 15 min, then with 10 ml of 0.1 M Glycine pH 2.7 and again with PBS 
until pH reached 7.4. 20 ml of cell culture supernatant were added to the 
column until they completely entered the column then the Ab-depleted 
fraction (Flow-through) was collected and column was washed again with 
PBS for 10min. 
The antibody was then eluted in 0.1 M Glycine pH 2.7 monitoring OD in 
order to decide when to start collecting fractions. The eluates were 
immediately neutralised with Tris-HCl 1.5 M pH 8.8 (20 µl/ml). The 
collected fractions (Eluate) containing 5H5 antibody were stored for further 
analysis. Finally the column was washed with PBS for 15 min and stored in 
PBS-NaN3 (2%) at 4°C until next purification. 
Eluted fractions were analysed by SDS-PAGE on a 12% gel followed by 
Coomassie staining with BioSafe Coomassie (Bio-Rad). 
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Fractions from different runs containing the antibody were pooled 
together and concentrated using Centriprep-3 (Amicon) or Vivaspin-20 (30 
KDa cut-off) (Sartorius) concentrators following manufacturer's 
instructions. 
6. Purification of factor H  
6.1. Preparation of 5H5-affinity column  
Concentrated antibody preparations were desalted using EconoPac DG10 
columns (Bio-Rad), according to the following protocol: 
1. Remove the upper cap, and pour off the excess buffer above the top frit. 
2. Add 20 ml of coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.4) to the 
column (fill to the 30 ml mark), and snap off the bottom tip to start the 
column flowing. 
3. Allow the buffer to drain to the top frit. The column will not run dry. 
Flow will stop when the buffer level reaches the top frit. 
4. Add 3.0 ml of concentrated antibody to the column. 
5. Allow entire sample to enter the column and discard the first 3.0 ml of 
effluent. 
6. Add 4.0 ml of coupling buffer to elute the antibody, while collecting the 
4.0 ml fraction from the column.  
Protein amount from concentrated fractions before and after desalting was 
determined by Bradford Protein assay (Bio-Rad). 
Column preparation: 
1. Collect 500 mg of Cyanogen Bromide-Activated Sepharose 4B resin 
(Sigma) into a 50-ml tube  
2. Washed four times with 50 ml of 1 mM HCl 
3. Leave the last wash in incubation for 10 min 
4. Filter the resin on a Büchner funnel 
5. Wash with milliQ water 
6. Wash with coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.4) 
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7. Collect washed resin into a 15-ml tube and resuspend it in 10 ml of 
coupling buffer containing 5 mg of desalted 5H5 antibody 
8. Incubate at RT in agitation for 2h 
9. After incubation, collect the coupling buffer with unbound antibody 
10. Wash the resin twice with coupling buffer 
11. Incubate the resin in 0.2 M Glycine pH 8.0 overnight at 4°C 
12. Wash the resin alternatively with coupling buffer/acetate buffer (0.1 M 
acetic acid, 0.5 M NaCl, pH 4.0) four times 
13. Put the resin into a column and equilibrate with PBS for 15min. 
14. Store the prepared 5H5-Sepharose column in PBS-NaN3 (2%) at 4°C 
until use. 
6.2. Purification of factor H  
Human factor H was purified from human serum by affinity 
chromatography on 5H5-Sepharose column. A set up of the protocol was 
necessary to achieve an efficient purification without any contaminant. It 
was necessary to test different elution protocols changing pH and salt 
concentration of solutions in order to obtain a perfectly purified protein. 
The final protocol is the following. 
The 5H5-Sepharose column was attached to the Econo-System (Bio-Rad) 
and washed at 1 ml/min first with PBS for 10 min, then with 10 ml of 0.1 M 
Glycine pH 2.7 and finally with 0.5 M NaCl in PBS until pH reached 7.4. 
Before adding it to the column 2 ml of human serum were brought to a 
final concentration of 0.5 M NaCl and filtered through 0.22 µm filters. The 
filtered human serum was allowed to completely enter the column at 0.25 
ml/min rate, then the column was washed with 0.5 M NaCl in PBS at 1 
ml/min rate and the fraction of FH-depleted serum (about 15 ml) was 
collected until OD dropped. Finally FH was eluted from the column with 0.1 
M Glycine pH 3.0 at 1 ml/min monitoring OD to decide when to start the 
collection, typically 6 ml of eluate (Purified Factor H) were collected. The 
eluate was immediately neutralised with Tris-HCl 1.5 M pH 8.8 ( 20 µl/ml). 
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The column was further washed with 0.1 M Glycine pH 2.7 in order to 
eliminate possible contaminants and finally washed with PBS and stored in 
PBS-NaN3 (2%) at 4°C until next purification. 
Eluted fractions were analysed by SDS-PAGE on a 8% gel in reducing and 
non-reducing conditions followed by Coomassie staining with BioSafe 
Coomassie (Bio-Rad). 
Positive fractions containing purified FH were pooled together and 
concentrated using Vivaspin-20 (30 KDa cut-off) concentrators (Sartorius) 
following manufacturer's instructions. 
7. Factor H ELISA 
A home-made ELISA test to determine FH concentration in biological fluids 
was developed. This assay is a sandwich ELISA that uses MAb 5H5 as the 
catcher and a FH-specific chicken antibody, also produced in our lab, as the 
tracer together with 5H5-affinity purified FH as a standard. 
Several adaptations have been made to the protocol to achieve the best 
results. Tris-Buffered Saline (TBS) pH 7.65 has been shown to be a better 
coating buffer than the traditional carbonate/bicarbonate buffer pH 9.6 for 
5H5 antibody. The use of an HRP-conjugated secondary antibody instead of 
the previously used AP-conjugated, and the consequent change of 
chromogenic substrate from BluePhos® to TMB enhanced the sensitivity of 
the test. 
Controls without coating and without FH were also included during the set 
up to assess test’s specificity. 
The final detailed protocol is described in the appendix. 
When aqueous humour and vitreous humour samples were used in the 
test, working dilutions were as follows: 
- aqueous humour: 1:5 and 1:10 
- vitreous humour: 1:5, 1:10 and 1:50 
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8. IgG and Albumin Depletion 
Albumin and IgG were depleted from normal human serum using Hi-Trap™ 
Albumin & IgG depletion columns (GE Healthcare) according to the 
following protocol. 
Buffers: 
- Binding buffer: 20 mM sodium phosphate, 0.15 M NaCl, pH 7.4 
- Elution buffer: 0.1 M glycin-HCl, pH 2.7 
Sample preparation: 
Human serum was centrifuged at 14,000 g for 10 min. at 4°C to eliminate 
debris and 150 µl were diluted 1:10 in binding buffer. 
Depletion procedure: 
The column was connected to a peristaltic pump and a flow rate of 1 
ml/min was used for the entire procedure. 
A modified protocol from the manufacturer datasheet was used as follows: 
1. Fill the pump tubing with binding buffer. Remove the stopper and the 
snap-off end from the column and connect it to the pump tubing 
'drop-to-drop' to avoid introducing air into the system. 
2. Wash the column with 5 ml binding buffer to remove the 20% ethanol 
storage solution. 
3. Equilibrate with 10 ml of binding buffer. 
4. Apply the diluted human serum to the column aspirating it directly 
from the tube and then wash with 7 ml of binding buffer. Collect the 
flow through (depleted serum) during sample application and wash 
(total 8.5 ml). 
5. Elute albumin and IgG from the column with 5 ml elution buffer and 
immediately neutralise with 100 µl Tris-HCl 1.5 M pH 8.8. 
9. Western Blot (WB) 
Serum samples and samples deriving from different purification 
procedures were subjected to SDS-PAGE in both reducing and non-
reducing conditions. For SDS-PAGE precast 4-12% or 12% NuPAGE® Novex® 
  
49 
Bis-Tris Protein Gel (LifeTechnologies) Mini or Midi were used and run in 
MOPS 1X buffer at 200 V for 40-60 min. depending on the different gels 
and formats. 
Gels were blotted on a PVDF membrane using iBLOT (LifeTechnologies) 
with protocol P3 for 7-10 min. Membranes were blocked with 3% BSA in 
TBS/Tween 0.5% 2h RT or overnight at 4°C. 
Different primary antibodies were used (Table 1) to reveal FH, FHRs, C3b 
and FI. Primary antibodies were typically diluted in 1% BSA in TBS/Tween 
0.5% and applied to the membranes 1h RT in constant agitation. 
Membranes were then washed 3 times with TBS/Tween 0.1% and 
incubated 1h RT in constant agitation with the corresponding Alkaline 
phosphatase (AP) conjugated secondary antibody diluted in 1% BSA in 
TBS/Tween 0.5%. After 3 washes in TBS/Tween 0.1%, specific signal was 
revealed with SigmaFast™ BCIP/NBT (Sigma). 
Table 1. Antibodies 
Protein Primary Antibody  Company Dilution Notes 
FH 5H5 MAb Our laboratory 1:15000 Specific for FH 
 chicken anti-FH PAb Our laboratory 1:10000 Specific for FH 
 sheep anti-FH PAb TheBindingSite 1:2000 Sees also two 
unspecified bands 
around 75 KDa 
FHR-1 rabbit anti-CFHL1 PAb Abcam 1:1000 Sees also FHR-2 
 rabbit anti-CFHR1 PAb Abnova 1:500 Sees also FHR-2 
FHR-2 rabbit anti-CFHR2 PAb Abnova 1:500 Sees also FHR-1 
FHR-3 rabbit anti-CFHR3 PAb ProteinTech 1:500 Sees FH, FHR-3 
band is uncertain 
FHR-4 rabbit anti-CFHR4  PAb Abcam 1:500 Sees also FH 
FHR-5 rabbit anti-CFHR5 PAb Abnova 1:500 Specific for FHR-5 
FI mouse anti-FI 
(Supernatant) 
MAb Serotec 1:100  
 sheep anti-FI PAb Sigma 1:2000  
C3b goat anti-C3 PAb Sigma 1:2000 Sees different 
fragments of C3 
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10. Factor H Immunoprecipitation (IP) 
To isolate FH from patients’ sera an IP micro-method was developed using 
5H5-Sepharose resin, in order to allow purification from small amounts of 
sample. The final standard IP protocol was as follows: 
1. Incubate in a 2.0-ml eppendorf tube 50 µl of serum or plasma with 50 µl 
of 5H5-sepharose resin in 500 µl of PBS for 30 min on a rotator mixer 
2. Centrifuge samples for 2 min at 13,000 rpm in a table-top 
microcentrifuge 
3. Collect in a new tube supernatant containing FH-depleted serum 
4. Wash resin once with PBS/Triton 0.1% and three more times with PBS, 
at each round centrifuge the tubes for 1 min at 13,000 rpm to pellet the 
resin and discard the wash buffer 
5. Elute FH from the resin with 200 µl of 0.1 M Glycine pH 2.7, incubating it 
for 15 min on a rotator mixer and centrifuge the tubes for 1 min at 
13,000 rpm to recover the eluate 
6. Transfer the eluate into a new tube contain 4 µl of Tris-HCl 1.5 M pH 8.8 
to neutralise it 
7. Perform a second elution step in the same conditions to ensure that all 
the FH is eluted from the resin 
8. Wash the resin several times with PBS 
The method was further developed by the use of Micro Bio-Spin™ Columns 
(Bio-Rad) which allow for a faster procedure. The final protocol was as 
follows: 
1. Incubate in the capped micro column 50 µl of serum or plasma with 50 
µl of 5H5-sepharose resin in 500 µl of PBS for 30 min on a rotator mixer 
2. Snap off the tip and place the column in a 1.5 ml eppendorf tube to 
collect the “FH-depleted serum”. Remove the cap and push it back on 
the column to start the flow. Allow the sample to flow by gravity 
through the column and eventually centrifuge for 30-60 sec. at 1,000 g 
to allow all the sample to pass. 
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3. Wash resin once with PBS/Triton 0.1% and three more times with PBS 
allowing the buffer to flow by gravity through the column, after the final 
wash centrifuge for 30-60 sec. at 1,000 g to allow all the buffer to pass. 
4. Place the column into a new tube contain 4 µl of Tris-HCl 1.5 M pH 8.8 
and elute FH from the resin with 200 µl of 0.1 M Glycine pH 2.7, 
allowing the sample to flow by gravity through the column and 
eventually centrifuge for 30-60 sec. at 1,000 g to allow all the sample to 
pass. 
5. Repeat the previous step once 
6. Wash the resin several times with PBS 
11. Heparin and hydrophobic interaction chromatography 
(HIC) purification 
In order to compare our results, factor H was purified using two other 
methods (Heparin and HIC) which don’t provide a complete separation of 
FH from FHRs proteins. 
11.1. Heparin purification 
Heparin purification was performed by the use of HiTrap Heparin HP 
Columns (GE Healthcare). 
Method overview: 
As FH and FHRs contain binding sites for Heparin with different binding 
affinity, they can be purified from serum by affinity chromatography on 
Heparin. Other serum proteins are also able to bind heparin are they can 
therefore be purified together with FH and FHRs. To separate proteins 
according to their binding capacity different salt concentrations can be 
used in the elution steps. The resin in the column is composed of Heparin 
covalently coupled to highly cross-linked agarose beads. Heparin used as a 
ligand is a naturally occurring sulphated glucosaminoglycan which is 
extracted from the native proteoglycan of porcine intestinal mucosa. It 
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consists of alternating units of uronic acid and D-glucosamine, most of 
which are substituted with one or two sulphate groups. 
Protocol: 
The protocol of the manufacturer was slightly modified as follow. 
Buffers: 
- Binding buffer: 10 mM sodium phosphate, pH 7 + 50 mM NaCl 
- Elution buffer: 10 mM sodium phosphate pH7 + NaCl 
 E1 100 mM NaCl 
 E2 150 mM NaCl 
 E3 200 mM NaCl 
 E4 250 mM NaCl 
 E5 300 mM NaCl 
 E6 400 mM NaCl 
 E7 500 mM NaCl 
 E8      1  M    NaCl 
Sample preparation: 
300 µl of human serum were diluted 1:10 in binding buffer and filtered 
through a 0.45 μm filter immediately before to be applied to the column. 
15 ml IgG-Albumin depleted serum, which correspond to 300 µl of 
undiluted serum were brought to a final NaCl concentration of 50 mM 
before being applied to the column. 
Purification procedure: 
The column was connected to a peristaltic pump, a flow rate of 0.5 ml/min 
was used for sample loading whereas 1 ml/min was used for washing and 
elution. 
1. Fill the pump tubing with binding buffer. Remove the stopper and 
connect the column to the pump tubing, “drop to drop” to avoid 
introducing air into the column. 
2. Remove the snap-off end at the column outlet. 
3. Wash out the preservative and equilibrate the column with 10 column 
volumes of binding buffer. 
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4. Apply the sample into the column aspirating it directly from the tube 
5. Collect the flow through (F.T.) into a new tube 
6. Wash with 10 ml of binding buffer 
7. Elute different fractions using 5 ml of each elution buffer and wash after 
each step with 5 ml of the same buffer 
8. Store all the samples (F.T. and Eluates) for further analysis 
All the fractions were then concentrated and desalted in PBS Buffer using 
Vivaspin-500 (5 KDa cut-off) (Sartorius) concentrators following 
manufacturer's instructions. Fractions were subsequently analysed by SDS-
PAGE followed by Coomassie staining with BioSafe Coomassie (Bio-Rad), 
and later by WB. 
11.2. Hydrophobic interaction chromatography (HIC) 
For HIC purification a column containing Macro-Prep Methyl HIC Support 
(Bio-Rad) was prepared, serum was loaded in the presence of ammonium 
sulphate and different fractions were eluted by gradually diminishing the 
salt concentration. 
Method overview: 
Hydrophobic interaction chromatography (HIC) separates proteins on the 
basis of their relative hydrophobicity. The principle for protein adsorption 
to HIC media is complementary to ion exchange and size exclusion 
chromatography. Sample molecules containing hydrophobic and 
hydrophilic regions are applied to an HIC column in a high-salt buffer. The 
salt in the buffer reduces the solvation of sample solutes. As solvation 
decreases, hydrophobic regions that become exposed are adsorbed by the 
media. The more hydrophobic the molecule, the less salt is needed to 
promote binding. Usually a decreasing salt gradient is used to elute 
samples from the column in order of increasing hydrophobicity.  
FH has been shown to bind to hydrophobic resin and therefore can be 
isolated with this procedure [163]. 
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The Macro-Prep Methyl HIC Support which is ideal for purifying proteins 
that have strong hydrophobic regions was chosen for this procedure. 
Buffers: 
- Buffer A: 10 mM Tris, pH 7.2 + 1.5M Ammonium Sulphate 
- Buffer B: 10 mM Tris, pH 7.2 
Column preparation: 
The Macro-Prep Methyl HIC Resin was resuspended into storage buffer 
(50% slurry) and packed into a column. The column was extensively 
washed with Buffer B and later equilibrated with Buffer A. 
Sample preparation: 
1 ml of human serum was diluted 1:3 into Buffer A and brought to 1.5 M 
(NH4)2SO4 adding 200 mg Ammonium Sulphate. The tube was left in the 
end-to-end platform until the salt was dissolved. The sample was 
centrifuged at 15,000 g for 15 min. to recover precipitates whereas the 
supernatant was used for chromatography.  
Setting up the Econo Chromatography System:  
The column was connected to Econo-System (Bio-Rad) and the sample 
supernatant (about 2.5 ml) was directly loaded on the Methyl HIC column. 
Flow through which doesn’t bind to the column was collected (100% 
Fraction). A gradient, mixing Buffer A and Buffer B in order to gradually 
diminish Ammonium Sulphate content, was set on the instrument and 
three fractions (66%, 33% and 0%) were collected monitoring OD280. 
Collected fractions: 
• 100%   1.5 M Ammonium Sulphate 
• 66%   1 M Ammonium Sulphate 
• 33%   0.5 M Ammonium Sulphate 
• 0%   no Ammonium Sulphate 
All the fractions were concentrated and desalted in Buffer B using Vivaspin-
500 (5 KDa cut-off) (Sartorius) concentrators following manufacturer's 
instructions. Fractions were subsequently analysed by SDS-PAGE followed 
by Coomassie staining with BioSafe Coomassie (Bio-Rad), and later by WB. 
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12. Factor H integrity assay 
FH (150 KDa) can be cleaved by a serum protease between amino acids 
341-342, thus generating two fragments (142 KDa and 38 KDa) that are 
held together by a disulphide bridge and are visible as separate molecular 
species only after reduction. This cleavage can be mimicked in vitro by 
trypsin. In order to develop a test capable of detecting the presence of the 
cleaved form of FH it was necessary to test the ability of 5H5 to bind it, 
using trypsin-cleaved FH. 
12.1. Trypsin cleavage of FH 
Reagents: 
• Trypsin TPCK treated from bovine pancreas (Sigma - T1426) - 1mg/ml in 
1mM HCl 
• Trypsin inhibitor from Glycine max (soybean) (Sigma - T9003) - 1mg/ml 
in H2O 
• 5H5-affinity purified FH 
Protocol: 
Trypsinization of FH was performed with a FH:trypsin ratio of 100:1 (w/w) 
(1 µg of FH + 10 ng of trypsin) in TBS pH 7.5, incubating at 37°C for different 
times. 
Digestion was stopped by adding twofold weight excess of soybean trypsin 
inhibitor. 
12.2. IP of Trypsin-cleaved FH 
A sample with 50% of trypsin-cleaved FH was immunoprecipitated with 
5H5-coupled Sepharose resin, as described previously. Samples before IP, 
and different fractions of IP were analysed by SDS-PAGE followed by 
Coomassie staining and densitometric analysis with the program TotalLab. 
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12.3. Integrity assay 
After demonstrating that 5H5 recognizes and immunoprecipitate with the 
same affinity both the uncleaved and cleaved form of FH, this important 
feature was used to set up a test for the integrity of FH in different 
samples. 
The test consists in the 5H5-affinity immunoprecipitation of FH from serum 
samples or from FH preparation followed by SDS-PAGE and Coomassie 
staining. A 50% trypsin-cleaved FH is used as a control. 
13. Factor H functional assays 
Two tests to screen N-terminal cofactorial activity and C-terminal 
protection activity of FH have been set up, namely the “Cofactor assay” 
and the “Haemolysis test”. 
13.1. Quantification of Purified Factor H 
The exact quantification of purified FH samples was a crucial point in order 
to perform the functional assays. Different quantification methods were 
used and compared: Bradford method with Bio-Rad protein assay, our 
home-made FH ELISA and spectrophotometric determination at 280 nm. 
Bio-Rad protein assay was performed following manufacturer instructions, 
the home-made ELISA developed for serum and plasma sample was used 
as described previously. 
Spectrophotometric determination was done with a Nanodrop instrument. 
PBS was used as a blank and absorbance at 280 nm was measured. To 
establish FH concentration an extinction coefficient for a 1% solution (E1%) 
of 12.4 was used, as reported by others [164]. 
This formula was used to calculate the concentration expressed in µg/ml: 
c = (A280/E1% * 10) * 1000 
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13.2. Cofactor assay: 
This test is based on the fact that FI can cut C3b in vitro only in the 
presence of FH; if FH is not functional C3b cannot be cleaved. 
All the samples to be used in this test were brought into PBS buffer and 
their concentration was established as previously reported. 
In the test we used purified C3b and FI (Merck Millipore) and 5H5-affinity 
purified FH. 
The test was set up with different amounts of purified proteins and with 
different incubation times. FH concentration was gradually scaled down to 
assess test sensitivity. 
The final protocol used to screen samples was as follows: 
500 ng of purified C3b and 250 ng of purified FI were incubated in PBS for 
30 min at 37°C alone or in the presence of different amounts of 5H5-
affinity purified FH. After incubation samples were put on ice and SDS 
sample buffer was immediately added to stop the reaction. Samples were 
loaded on a SDS-PAGE gel and analysed by WB using a polyclonal anti-C3b 
antibody (Sigma) or by Coomassie staining. 
13.3. Haemolysis test 
This test to assess the activity of the C-terminus is based on the fact that FH 
is able to protect Sheep erythrocytes from complement attack. If 
complement is activated erythrocytes undergo lysis that can be measured 
by the release of haemoglobin using a microplate reader. 
The test has been first set up using a control serum with known amount of 
functional FH. Protocol was adapted from “AH50 Assay for Total Alternative 
Pathway Hemolytic Activity” Giclas (2001) [165]. 
Due to the impossibility to purchase Veronal buffer that is normally used in 
this kind of test it was necessary to set up the test using two different 
buffers: 
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- A modified Veronal buffer adapted using a commercially available buffer 
similar to the one needed: Veronal Buffer 5X (Lonza) 
- HEPES buffer adapted from Moreno-Indias et al. [166] 
The final detailed protocol is described  in the appendix. 
The test was then performed adding different concentration of EDTA to 
serum. This was necessary to test the minimum concentration of EDTA that 
still allows lysis, since depleted serum needs to be prepared in the 
presence of EDTA in order to prevent complement activation during the 
procedure. 
The final part of the test that makes use of FH-depleted serum alone or 
with different amounts of FH to be tested is still under development. 
14. Cloning of factor H 
The sequence of human factor H RNA (NM_000186.3) has been divided 
into three main fragments containing approximately 7 SCR each (SCR 1-7, 
SCR 8-14, SCR 15-20) and specific PCR primers were designed (Table 2). 
Quality and specificity of primers was checked with Primer Premier 
software (Primer Biosoft). 
14.1. Retrotranscription 
Human Liver total RNA (Life Thechnologies) was retrotranscribed with two 
methods: iScript cDNA Synthesis Kit (Bio-Rad) which contains a mix of 
Random Hexamers and Oligo(dT) or with ImProm-II™ Reverse Transcription 
System (Promega) which enables the use of Oligo(dT) or Specific primers in 
different reactions. A modified protocol was used. 
14.1.1. RNA denaturation 
Samples for different retrotranscription reactions were prepared as follows 
and denatured at 70°C for 5 min followed by a 10 min incubation on ice. 
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 cDNA-1 
(ImProm) 
cDNA-2 
(ImProm) 
cDNA-3 
(iScript) 
Oligo(dT)15 1 µl - - 
FH-specific 
primers 
- 1 µl - 
RNA 1 µl 1 µl 1 µl 
Nuclease free 
H2O 
3 µl 3 µl 4 µl 
 
14.1.2. Retrotranscription reactions 
Different reaction mixes were prepared and added to the samples: 
RT mix ImProm   RT mix iScript  
5x ImProm reaction buffer 4 µl  5x reaction mix 4 µl 
MgCl2 2.5 µl  iScript RT 1 µl 
dNTPs 1 µl  Nuclease free H2O 5 µl 
RNAse Inhibitor 1 µl    
ImProm RT 1 µl    
Nuclease free H2O 5.5 µl    
 
Retrotranscription was performed with the following thermic protocol: 
25° C 5’  
42° C 60’ 
85° C 5’  
 
cDNA quality was checked by PCR using beta-actin primers when possible. 
 
14.2. Amplification 
The entire FH and the three fragments have been amplified using Phusion™ 
DNA Polymerase (Thermo). Regular HF buffer was substituted with CG 
Buffer, which is normally used for difficult templates, as FH cDNA tends to 
form secondary structures and amplification results challenging. 
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Mix   Thermic protocol  
5x CG buffer 4 µl  98° C 30”  
dNTPs (10mM) 0.4 µl  98° C 10”  
Primer F (10µM) 1 µl * 64° C 20” X 35 
Primer R (10µM) 1 µl  72° C 50”*  
Phusion 0.2 µl  72° C 5’  
cDNA 2 µl     
dH2O up to 20 µl     
* for the amplification of the entire FH 0.8 µl of dNTPs and 2’ extension 
were used. 
Amplification products were checked and quantified on a agarose gel. 
14.3. Features of the pFastBac™/HBM-TOPO® vector 
The pFastBac™/HBM-TOPO® vector (Life Technologies) was chosen for 
cloning and expression into insect cells. The vector contains the following 
elements: 
• Strong polyhedrin (PH) promoter for high-level baculovirus-based 
protein expression in insect cells 
• TOPO® Cloning site for rapid and efficient cloning of blunt-end PCR 
products amplified with proofreading polymerases 
• N-terminal Honey Bee Mellitin (HBM) secretion signal coding sequence 
for secretion of the cloned gene product into the extracellular medium 
• C-terminal polyhistidine tag for simple purification of recombinant 
proteins 
• TEV protease cleavage site for removal of the polyhistidine tag 
following protein purification using AcTEV™ protease 
• SV40 polyadenylation signal for efficient transcription termination and 
polyadenylation of the recombinant transcript 
• Mini-Tn7 elements for site-specific transposition of the gene of interest 
into the baculovirus shuttle vector (bacmid DNA) propagated in E. coli 
• Ampicillin (bla) resistance gene (β-lactamase) for selection of 
transformants in E. coli 
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• pUC origin for high copy replication and maintenance of the plasmid in 
E. coli 
• Gentamicin resistance gene for selection of transformants containing 
recombinant bacmid DNA 
14.4. Blunt-End TOPO® Cloning Reaction 
The amplified fragments were inserted into the pFastBac™/HBM-TOPO® 
vector (Life Technologies) using TOPO-cloning.  
All the samples were brought to a concentration of 5 ng/µl and an 
insert:vector ratio of 2:1 was used in the in a TOPO® Cloning reaction. The 
6-µl reactions were prepared as follows: 
PCR Product (5 ng/µl) 4 µl 
Salt Solution (200 mM NaCl, 10 mM MgCl2) 1 µl 
pFastBac™/HBM-TOPO® vector 1 µl 
and incubated 5 min at RT. 
14.5. Transformation and analysis of tranformants 
The TOPO reactions were used to transform Mach1™ T1R Chemically 
Competent E. coli (Life Technologies) following the manufacturer protocol. 
Plates were incubated overnight at 37°C. 
Some colonies were screened by Colony PCR to check the orientation of 
the insert, two parallel PCR reactions were performed: 
- PCR Forward: which detects the fragment inserted in the correct 
orientation. 
In this PCR a forward primer on the insert together with SV40 reverse 
primer on the vector is used. (Table 2) 
- PCR Reverse: which detects the fragment inserted in the correct 
orientation 
In this PCR a reverse primer on the insert together with SV40 reverse 
primer on the vector is used, if the fragment is in the wrong orientation 
the reverse primer on the insert functions as a forward primer giving 
amplification. (Table 2) 
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After this first screening, plasmid DNA from positive ones was isolated by 
Mini-prep using Eurogold Plasmid kit (Euroclone) according to the 
manufacturer protocol. 
Plasmid DNA was then sequenced using primers located on the vector 
(Table 2) and sequences were analysed with CLC Sequence Viewer (CLC 
bio). 
14.6. Cloning into a prokaryotic system 
Primers to clone the same fragments into a prokaryotic system were also 
designed. (Table 2) 
These primers will be used to amplify the fragments directly from the 
previously generated pFastBac™/HBM clones, fragments will be 
subsequently inserted into E. coli expression vector using the StarGate® IBA 
System (IBA BioTAGnology). 
Table 2. Primers 
Primer Sequence (5’-3’) 
  
PCR primers for cloning into the eukaryotic system 
FH-SCR1-F GAAGATTGCAATGAACTTCCTC 
FH-SCR7-R GACACGGATGCATCTGG 
FH-SCR8-F GTCAAAACATGTTCCAAATCAAG 
FH-SCR14-R TTTTTCAACACAGAGTGGTATTG 
FH-SCR15-F AAAATTCCATGTTCACAACCAC 
FH-SCR20-R TCTTTTTGCACAAGTTGGATAC 
  
Colony PCR primers 
SV40 polyA-rev GGTATGGCTGATTATGATC 
Used together with PCR specific primers 
  
Sequencing primers 
pFASTBAC-F TCCGGATTATTCATACCGTCCC 
pFASTBAC-R CCTCTACAAATGTGGTATGGCTG 
  
PCR primers for cloning into the prokaryotic system 
Star-FH-SCR-1F AGCGGCTCTTCAATGGAAGATTGCAATGAACTTCCTC 
Star-FH-SCR-7R  AGCGGCTCTTCTCCCGACACGGATGCATCTGGGA 
Star-FH-SCR-8F AGCGGCTCTTCAATGGTCAAAACATGTTCCAAATCAAG 
Star-FH-SCR-14R  AGCGGCTCTTCTCCCTTTTTCAACACAGAGTGGTATTG 
Star-FH-SCR-15F AGCGGCTCTTCAATGAAAATTCCATGTTCACAACCAC 
Star-FH-SCR-20R  AGCGGCTCTTCTCCCTCTTTTTGCACAAGTTGGATAC 
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RESULTS 
15. Production and Purification of 5H5 antibody  
High density hybridoma cultures with CELLine Bioreactor enabled to 
produce a consistent amount of MAb 5H5, mean antibody production was 
about 1.5-2 mg/day. 
The quality of purified antibody checked by SDS-PAGE in reducing 
conditions followed by Coomassie staining was good, and purity was about 
90-100%. Two major bands are visible on the gel, a 50 KDa band 
corresponding to antibody’s heavy chains and a 25 KDa band 
corresponding to light chains, an upper band due to incomplete reduction 
can also be present. (Fig. 13) 
 
Fig. 13 Coomassie of purified MAb 5H5: two elution fractions are shown (El.1 
and El.2), antibody elute in the first fraction and bands corresponding to heavy (50 
KDa) and light (25 KDa) chains are clearly visible. 
MAb 5H5 antibody has been tested in Western Blot and fractions of total 
human serum, albumin- and IgG-depleted serum and albumin and IgG 
purified from serum have been analysed. Under non-reducing conditions a 
clear band around 150 KDa corresponding to FH is visible in total serum 
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and depleted serum. Both in total serum and in the fraction containing 
albumin and IgG a non-specific signal is present, due to cross-reaction of 
secondary antibody (anti-mouse IgG) with human immunoglobulins as 
confirmed by specific controls (Fig. 14). WB with MAb 5H5 was performed 
only in non-reducing condition as the antibody recognises a conformation-
dependent epitope. 
 
Fig. 14 WB of FH from human serum: fractions of total human serum (tot. ser), 
albumin- and IgG-depleted serum (dep. ser) and albumin and IgG purified from 
serum (IgG Alb) have been analysed with 5H5 antibody in non-reducing 
conditions. FH band around 150 KDa is visible in total serum and depleted serum, 
non-specific signal present in total serum and in IgG-albumin fraction is due to 
cross-reactivity of secondary antibody as shown by specific control on the left. (FH 
= complement factor H) 
16. Purification of FH  
Thanks to the high affinity of MAb 5H5 for FH, it was possible to setup a 
“one-step” purification which gives a highly pure protein, starting from 
total human serum. 
It has been necessary to refine the procedure in order to obtain a 100% 
pure preparation. Several buffers with different salt concentration and pH 
have been tested. 
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The addition of NaCl to a final concentration of 0.5 M into the binding 
buffer was shown to prevent unspecific binding to the 5H5-affinity column. 
The best elution buffer was found to be 0.1 M Glycine pH 3.0. At pH 4.0 
elution of FH is only partial whereas at pH 3.0 the maximum of elution is 
achieved, lowering the pH to 2.7 only traces of FH still elute (Fig. 15). If 
elution is performed directly at pH 2.7 also a small amount of serum 
albumin co-elutes with FH when purification is performed from total (non 
albumin-depleted) serum (data not shown). 
 
 A 
 B 
Fig. 15 Coomassie of purified FH (A): three fraction from different purifications at 
pH 3 (FH1, FH2 and FH3) and one residual fraction at pH 4 (FH4) are shown. 
Under non reducing conditions a single band corresponding to FH is visible at 150 
KDa. (B): Excluded fraction (Esc) and different elution fractions of factor H (E1-7) 
are shown both in non-reducing and reducing conditions. The maximum of elution 
is achieved at pH 3. 
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Efficiency of the method and purity of the affinity purified FH were checked 
by Western Blot. 
Western blot on total serum, purified FH fractions and FH-depleted serum 
was performed in non-reducing conditions with both MAb 5H5 and 
polyclonal chicken anti-FH. With both antibodies, a 150 KDa band is 
present in purified FH fractions whereas it is missing in FH-depleted serum, 
confirming that depletion was complete (Fig. 16). Non-specific signal due to 
cross-reaction of the polyclonal or the secondary antibodies with human 
immunoglobulins is present in total serum and FH-depleted serum (Fig. 16). 
 
 A                                                                   B 
Fig. 16 (A) WB of FH from human serum: fractions of total human serum (tot. 
ser), albumin- and IgG-depleted serum (dep. ser) and albumin and IgG purified 
from serum (IgG Alb) have been analysed with 5H5 antibody in non-reducing 
conditions. FH band around 150 KDa is visible in total serum and depleted serum, 
non-specific signal present in total serum and in IgG-albumin fraction is due to 
cross-reactivity of secondary antibody as shown by specific control on the left. (FH 
= complement factor H) (B) WB of purified FH: fractions of purified FH (FH) and 
FH-depleted serum (dep. ser) have been analysed in non-reducing conditions with 
both MAb 5H5 and polyclonal chicken anti-FH antibodies. FH band (150 KDa) band 
is present in purified FH fractions whereas it is missing in FH-depleted serum. 
Depletion of FH from serum and efficiency of purification was also checked 
in an ELISA test using purified FH as a standard for precise quantification 
(Fig. 17). 
As shown in Figure 17, a single step of affinity chromatography was able to 
almost totally deplete the sample of FH, less than 1 µg/ml is still present in 
depleted serum.  
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  A                                                          B 
Fig. 17 FH ELISA from depleted serum: OD at different dilutions of FH-depleted 
serum compared to purified FH (A) and quantification of residual FH in FH-depleted 
serum alone or compared to total serum (B) are shown. 
Moreover purity of the fractions and absence of “contaminating” FHRs 
proteins was demonstrated by WB using antibodies against different FHRs 
proteins. The FH purified by 5H5-affinity chromatography was compared 
with fractions obtained with other purification methods such as Heparin-
affinity chromatography and HIC chromatography. In fractions obtained by 
5H5-affinity, unlike the ones coming from other purification methods, no 
FHRs proteins are present (Fig. 18). 
 
 Fig.18 WB of total serum and different fractions of 5H5-affinity purification 
and Heparin purification developed with antibodies for FH and FHRs: FHRs 
are completely absent in the 5H5-affinity purified FH indicated with the red arrow. 
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17. FH quantitative ELISA  
An ELISA assay for the specific quantification of serum FH was developed. 
This assay is a sandwich ELISA that uses MAb 5H5 as the catcher and a FH-
specific chicken antibody, also produced in our lab, as the tracer. Serial 
dilutions of 5H5-affinity purified FH are used to generate a standard curve. 
This high specificity of the test is based on the fact that the MAb 5H5, 
which was shown to recognise only FH, is used in the solid phase. 
This test was fine tuned in order to achieve the maximum sensitivity. 
Efficiency of capture was higher when Microtiter plate coating was 
performed in TBS at pH 7.65 than it was carbonate/bicarbonate buffer pH 
9.6, which is the standard coating buffer, thus coating conditions were 
accordingly modified. The shift from AP-conjugated to an HRP-conjugated 
secondary antibody and the consequent change of chromogenic substrate 
from BluePhos® to TMB also enhanced the sensitivity of the test. The test 
was validated using control sera sample from human donors and turned 
out to be reliable, reproducible and with a very good dynamic range 
(almost three orders of magnitude). 
The assay was later used to quantify FH serum levels from aHUS patients 
and their relatives, compared to controls (Fig. 19). The analysis revealed a 
FH deficit in four patients, two of them with really low FH levels 
(<100µg/ml), in the other patients FH serum level was within the normal 
range.  
Finally the method was also used to quantify FH levels in different samples 
from AMD patients such as plasma, aqueous and vitreous humour. 
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Fig. 19 FH ELISA: Bar Graph representing FH serum levels in controls and aHUS 
patients are shown. In 4 patients FH levels are below the normal range (indicated 
by dotted bar). Mean of FH levels is significantly reduced in patients compared to 
controls 
18. Factor H Immunoprecipitation (IP) 
A micromethod to purify FH from small amounts of sample was developed 
using 5H5-coupled Sepharose resin. The minimum amount of plasma 
needed is 20 µl but the best results are achieved with 50 µl. The method 
resulted to be really efficient as FH is completely depleted from plasma and 
a single band corresponding to FH is present in the purified fractions (Fig. 
20). 
 
Fig. 20 FH IP: IP from 4 plasma samples; total plasma, FH-depleted plasma and 
immuoprecipitated FH are shown. Depletion of FH from plasma is complete as 
shown by the arrow 
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The method was further improved by the use of Micro Bio-Spin™ Columns 
(Bio-Rad) which allow for a faster procedure. 
19. Trypsin cleavage and integrity assay 
19.1. Cleavage of FH by trypsin 
FH (150 KDa) can be cleaved by a plasmatic protease into two fragments 
(142 KDa and 38 KDa) that are held together by a disulphide bond. This 
cleavage can be mimicked in vitro by trypsin. In order to develop a test to 
detect the presence of cleaved FH it was necessary to obtain trypsin-
cleaved FH. 5H5-affinity purified FH was subjected to digestion with trypsin 
using different incubation times and samples were analysed by SDS-PAGE 
under reducing conditions followed by Coomassie staining. 
As the incubation time increases the band corresponding to intact FH (180 
KDa, in reducing conditions) decreases, whereas the bands corresponding 
to the two cleaved fragments (142 KDa and 38 KDa) appear. The 50% of 
cleavage is achieved after only 5 min. Increasing again the time other 
bands due to other cuts performed by trypsin also appear fractions (Fig. 
21). 
  
Fig. 21 Trypsin cleavage of FH: trypsin cuts FH into two fragments, as the 
incubation time increases the cleaved form increases compared to the uncleaved 
form. 
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19.2. Affinity of 5H5 for cleaved and uncleaved FH 
To test the ability of 5H5 to bind both the cleaved and uncleaved form, 
affinity purified FH was cleaved in vitro with trypsin for 5 min. in order to 
obtain 50% of cleavage and subsequently immunoprecipitated with 5H5-
coupled Sepharose resin. Analysis of immunoprecipitated samples on 
reducing SDS-PAGE followed by Coomassie staining revealed that the 
antibody is able to bind and immunoprecipitate both forms fractions (Fig. 
22). Moreover, to assess the affinity of 5H5 for the two forms, gels were 
analysed by densitometry with the TotalLab program. This analysis 
revealed that 5H5 binds both forms with the same affinity, this is probably 
due to the fact that the antibody recognises only the non-reduced FH in 
which the two fragments of the cleaved form are held together by a 
disulphide bond. 
   
Fig. 22 IP of trypsin-cleaved FH: both bands bind with the same affinity to 5H5 
Mab and are eluted from the beads (E1). A small amount is present in the second 
elution (E2) and in the not-bound (N.B.) fraction. 
19.3. FH integrity assay 
The ability of 5H5 to immunoprecipitate with the same affinity both forms 
was exploited to set up a test to check integrity of FH in different samples, 
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such as patient’s sera or FH preparations obtained with other purification 
methods. 
FH was immunoprecipitated from 16 aHUS patients and their relatives and 
protein integrity was verified on a SDS-PAGE followed by Coomassie 
staining, the analysis revealed that all the patients possess the intact form 
(Fig. 23). 
 
Fig. 23 aHUS FH-IP: FH immunoprecipitated from aHUS patients in comparison 
with entire FH and trypsin-cleaved FH. All the patients possess the intact form. 
The same method was used to test some FH preparations obtained with a 
purification procedure consisting of two chromatography steps. The 
analysis revealed that these samples contain also the cleaved form of FH, 
the amount of which was ranging from 5 to 25% depending on different 
preparations (Fig. 24). 
 
Fig. 24 FH-IP from FH preparations. FH immunoprecipitated from FH 
preparations obtained with biochemical methods. The samples have different 
amounts of cleaved FH. FH = purified FH; FHT = trypsin-cleaved FH 
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20. Quantification of Purified Factor H 
The exact quantification of purified FH samples was a crucial point in order 
to perform the functional assays and to compare different samples. 
Different quantification methods were compared. Bradford assay turned 
out to be totally unreliable for this purpose, whereas ELISA and 
spectrophotometric determination at 280 nm were more reliable and gave 
comparable results. ELISA resulted to be the most sensitive method as it 
was possible to quantify low FH concentrations. However, OD280 was 
sensitive enough to quantify FH samples to be used for functional assays 
and was in general preferred as it is faster. 
21. FUNCTIONAL ASSAYS 
Two assays to test respectively the N-terminal cofactorial activity of FH and 
its C-terminal protective activity were developed. 
21.1. Cofactor assay 
A “cofactor assay” to assess N-terminal functionality of FH making use of 
purified C3b and FI was set up. FI is able to cut C3b converting it to the 
inactive form iC3b only in the presence of its cofactor FH. C3b is composed 
of two chains: α’-chain (104 KDa) and β-chain (70 KDa), the α’ is cleaved by 
FI into two fragments, α-68 (68 KDa) and α-43 (43 KDa).  
Purified C3b was incubated with FI alone or together with different 
amounts of FH and the presence of different bands was checked on a 
reducing SDS-PAGE followed by WB with a polyclonal antibody against C3b. 
In the absence of FH (C3b and C3b + FI) the α’-chain is not cleaved and a 
single band around 104 KDa (α’) is observed whereas in the presence of FH 
(C3b + FI + FH) α’ is cleaved and a faint band around 104 KDa is still visible 
but α-68 and α-43 are also visualized (Fig. 25). In all the samples a band of 
70 KDa corresponding to β-chain is also present and remains constant. 
  
74 
 
Fig. 25 Cofactor assay: Cofactor assay to assess functionality of FH, C3b is 
cleaved by FI only in the presence of FH. Without FH (C3b and C3b + FI) the α’-
chain is not cleaved and a single band around 104KDa (α’) is observed, with 
different amounts of FH (C3b + FI + FH) α’ is cleaved and a small band around 
104KDa is still present but α-68 and α-43 are also visualized. The β-chain band at 
70KDa is also present in all the samples 
Different amounts of FH were used in the test to find the minimum 
quantity of FH which is still able to act as cofactor for FI. Samples were 
analysed both in WB and by Coomassie staining and results were compared 
(Fig. 26). Test sensitivity was high also in Coomassie staining and presence 
of other bands corresponding to FI heavy (50 KDa) and light (38 KDa) 
chains, not visible in WB, didn’t interfere as they migrate under the C3b 
bands used for the analysis. For these reasons and because the Coomassie 
method is much faster, this was used for the following tests. 
 
Fig. 26 Cofactor assay developed in WB (A) or Coomassie (B): the two 
methods give comparable results. 
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Gels were analysed by densitometry with the TotalLab program and the 
intensity of α’-chain or α-68 band was compared to that of β-chain (70 
KDa) which remains constant. The cofactor activity was calculated as a 
decrease of α’-chain or an increase of α-68. The first one was preferred as 
the α’-chain is subject to a single cut by FI, whereas α-68 can be further 
cleaved into α-27 and C3dg. 
To assess functionality of different FH samples, cofactor assay was 
performed in parallel on test samples and 5H5-affinity purified FH as a 
control. A sample in which FH was absent was always included for 
quantification of the results. At least three different concentrations of FH 
were used for each sample. 
The percentage of α’/β was calculated as follows: the intensity of α’ band 
was first normalised to the intensity of β band in each lane and then 
divided by the α’/β ratio obtained in the control where FH was absent as 
this corresponds to 100% of α’-chain. 
Data corresponding to the percentage of α’/β relative to the ng of FH used 
were put on a graph and a Logarithmic regression model was used to build 
a curve using the equation: y = a + b ln(x), where y = % α’/β and x = ng FH. 
The curve was then visualized in a graph in which x-axis is in logarithmic 
scale (Log10) in order to visualize a straight line. The curve obtained allows 
the direct comparison of different samples. 
This test was used to compare different samples of FH purified by 5H5-
affinity IP from sera of normal donors. The analysis revealed that cofactor 
activity in these samples was normal and comparable to that of the control 
(Fig. 27-A).  
This test was also used to analyse some samples of FH, purified with a 
biochemical method consisting in a two-step chromatography, that were 
produced for therapeutic purpose. 
Different samples and different fractions coming from different purification 
steps were analysed and compared with a 5H5-affinity purified FH as a 
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control. The analysis revealed a decrease in cofactor activity in some of 
these samples, probably due to the purification procedure (Fig. 27-B). 
 
A 
 
B 
Fig. 27 Cofactor assay: (A) on 5H5-affinity purified FH and (B) on FH purified with 
biochemical methods. 
21.2. Haemolysis test 
An “Haemolysis test” to test the protective activity of FH, which depends 
on the C-terminal part of the molecule, was set up for sera samples. 
This test is based on the fact that FH is able to protect sheep erythrocytes 
from complement attack; in the absence of FH or in the presence of a 
defective FH erythrocytes undergo lysis which can be measured 
spectrophotometrically following the release of haemoglobin. 
A minimum of haemolysis is still observed using high concentrations of sera 
and can be used to test alternative pathway (AP) activation. 
The assay was first set up using a control serum to test all the conditions 
needed to develop the final test. 
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Due to the impossibility to purchase Sodium Barbital needed to prepare 
the right buffer for this assay, it was necessary to adapt the protocol using 
two different buffers (V-AP and H-AP). 
The first buffer used (V-AP) was a prepared Veronal buffer commercially 
available already containing Sodium Barbital. The formulation of this buffer 
was not ideal for this test, especially for the presence of Calcium that needs 
to be chelated. Some adaptations were made to the buffer in order to 
obtain a formulation the most similar to the one needed. The second 
buffer (H-AP) was made substituting Sodium Barbital with HEPES. 
Several dilutions of the control serum were tested in the two different 
buffers and two dilutions of heat-inactivated serum were used as controls 
for each buffer. Data were normalised subtracting the OD415 of the 0% lysis 
control (only buffer) and percentage of haemolysis was calculated relative 
to the 100% lysis control obtained by lysing erythrocytes with water. 
The test was functioning with both buffers and almost no haemolysis was 
present in heat-inactivated serum. Using the H-AP the percentage of 
haemolysis was higher (Fig. 28).  
 
Fig. 28 Haemolysis assay: assay performed with two different buffers. 
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In the final test FH-depleted serum needs to be used. Since subtracting FH 
from serum leads to an indiscriminate activation of complement with the 
consequence of consuming all the complement proteins, activation needs 
to be inhibited by adding EDTA throughout the depletion procedure. On 
the other hand, EDTA will also chelate Magnesium ions needed to activate 
AP in the haemolysis test. For these reasons, different concentrations of 
EDTA were tested in this assay in order to establish the minimum 
concentration that prevents activation of complement in FH-depleted 
serum but still allows the test to function. 
The test was performed diluting the serum 1:5 in H-AP buffer with the 
addition of different amounts of EDTA. As a negative control PBS was used 
instead of serum and prepared in the same way. Percentage of haemolysis 
was calculated as before and visualized on a graphic relative to final EDTA 
concentration (Fig. 29). 
 
Fig. 29 Haemolysis assay: assay performed with different EDTA concentrations. 
Haemolysis resulted to be inhibited by the presence of EDTA and decreases 
as the concentration of EDTA increases. A final concentration of 1 mM still 
allows the test to function. Considering that serum is used at a 1:5 dilution 
and is then diluted 1:1 with erythrocyte preparation, the final dilution is 
1:10. That allows to prepare depleted serum with 10 mM of EDTA and to 
perform the test with a final concentration of 1 mM. 
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22. Other purification methods 
22.1. Heparin affinity purification 
Human serum was applied to a Heparin column in order to purify heparin 
binding proteins such as FH and FHRs. Fractions were analysed by WB with 
different antibodies for FH, FHRs and C3b (Fig. 30). All the proteins were 
present in serum before purification and some traces were still present in 
the flow through probably due to column overload. FH eluted at 250 mM 
NaCl with some residual at higher salt concentrations (300-400 mM). FHR-1 
eluted both at 250 and 300 mM NaCl with some residual at 400 mM, 
whereas FHR-2 eluted at 250 mM together with FH and no residuals were 
visible at higher salt concentrations. FHR-5 had a different pattern as is 
eluted at higher salt concentrations with a maximum at 300 and 400 mM 
and only a small amount eluted earlier. Finally FHR-4 didn't seem to bind to 
the Heparin column as all the signal was present in the flow through. 
 
Fig. 30 WB of Heparin fractions developed with antibodies for FH and FHRs. 
C3b eluted together with FH at 250 mM NaCl with some traces at higher 
salt concentrations. (data not shown) 
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22.2. Hydrophobic Interaction Chromatography (HIC) 
Serum proteins were also isolated with a hydrophobic column (HIC) and 
fractions were analysed by Coomassie staining and by WB with different 
antibodies for FH, FHRs and C3b (Fig. 31). 
Albumin did not bind to HIC column and is present in the 100% fraction 
containing 1.5 M ammonium sulphate. FH and FHRs eluted in the 33% 
fraction containing 0.5 M ammonium sulphate except FHR-5 which was 
present in the 0% fraction. Finally C3b was present both in the 66% and 33 
% fractions (1 and 0.5 m sodium sulphate) with a residual of α-43 in the 0% 
fraction.  
 
Fig. 31 Coomassie e WB of HIC fractions.(A) Coomassie, (B) WB for C3b and 
(C) WB for FH and FHRs. 
23. CLONING OF FACTOR H 
The entire FH and three fragments containing approximately seven SCRs 
each (SCR 1-7, SCR 8-14, SCR 15-20) have been amplified from human liver 
RNA using Phusion™ DNA Polymerase (Thermo). 
In order to obtain the right amplification of all the fragments in was 
necessary to introduce several changes in the protocols. cDNA was 
produced using both Oligo(dT) or specific primers: SCR-7R, SCR-14R, SCR-
20R. For SCR 1-7 fragment the best results were obtained using cDNA 
retrotranscribed with the specific primer SCR-14R whereas for fragments 
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SCR 8-14 and SCR 15-20 cDNA produced with the specific primer SCR-20R 
was used. (Fig. 32) 
 
Fig. 32 Amplifications of FH fragments. Amplification from cDNA obtained with 
specific primers FH-SCR14-R (RT14) or FH-SCR20-R (RT20). C
-
 = negative control. 
Finally for the amplification of the entire FH both cDNA retrotranscribed 
with Oligo(dT) or specific primer SCR-20R for a longer time gave good 
results. (Fig. 33) 
 
Fig. 33 Amplification of entire FH. Amplification from cDNA obtained with 
specific primer FH-SCR20-R (20) or OligodT (dT) primers. C
-
 = negative control.
 
All the amplifications with the proofreading polymerase were performed in 
CG buffer as the standard HF buffer gave poor results. This buffer is 
recommended for difficult templates that tend to form secondary 
structures. 
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Analysis of cDNA sequences with RNAfold program from the Vienna 
package [167] revealed the presence of secondary structures (Fig. 34) 
 
Fig. 34 Secondary structure of FH cDNA: graph obtained with RNAfold program 
All the fragments were correctly amplified and quantified on an agarose gel 
(Fig. 35) 
 
Fig. 35 Quantification of PCR products 
The amplified fragments were inserted into the pFastBac™/HBM-TOPO® 
vector (Life Technologies) using TOPO-cloning and used to transform 
competent E. coli. Clones were analysed by colony PCR to check the 
presence and the right orientation of the fragments. Two parallel PCR 
reactions were performed using one primer on the vector together with a 
forward or a reverse primer specific for the fragment. The clones that give 
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amplification in the PCR Forward but not in the PCR Reverse possess the 
fragment in the correct orientation (Fig. 36). 
 
Fig. 36 Colony PCR 
Plasmid DNA was extracted from positive clones and sent to a sequence 
service, sequences were analysed with CLC Sequence Viewer (CLC bio). 
Some clones were found to possess the correct sequences and selected for 
the following steps. 
Notably, the sequence of FH and of the SCR 1-7 fragment has been shown 
to possess the 402T allele (TAT codon) which is associated with a low risk of 
AMD, whereas the sequence present on NCBI database possesses the high 
risk allele 402H (CAT codon) (Fig. 37). 
 
Fig. 37 Sequencing results: the clones possess the low risk allele 402T. 
(Legend: FH_HBM-His = sequence of FH from NCBI inserted into the vector, FH 
(mature) = sequence of FH from NCBI, FH_5_F and FH_5_R = Forward and 
Reverse sequences of clone n. 5) 
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DISCUSSION 
Complement Factor H (FH) is a crucial regulator of complement activation. 
Mutations in the CFH gene are frequently associated with a number of 
human diseases, furthermore it has an important role in infectious diseases 
as many pathogens are able to recruit it on their surface to protect 
themselves from complement attack. 
However, the study of this protein is complicated by the presence of other 
homologous proteins belonging to the “FH protein family”. The high amino 
acid identity among the family members is a cause of cross-reactivity for 
antibodies. Antibodies raised against FH often detect also different FHRs 
and antibodies generated against FHRs can cross-react with FH or other 
FHRs. This cross-reactivity is thus a challenge for correct quantification 
and/or purification of FH from plasma. 
The aim of this study was mainly to develop some quantitative and 
functional FH-specific assays, using a monoclonal antibody (MAb 5H5) 
produced in our laboratory that was shown to be specific for FH. Another 
important focus was the production of recombinant FH in both an 
eukaryotic and a prokaryotic expression system, in order to study the 
importance of protein glycosylation and to further and more precisely 
refine structure-function relationships, as well as to develop safer 
therapeutic tools: in fact, current therapies for FH defects only rely on 
blood derivatives. 
By the use of high-density hybridoma cultures with CELLine Bioreactor, it 
was possible to produce a consistent amount of MAb 5H5. This antibody 
was the starting point for the development of FH-specific assays. 
The first use of MAb 5H5 was the purification of FH using the antibody 
conjugated with Sepharose resin. Thanks to the high affinity of MAb 5H5 
for FH, it was possible to set up a “one-step” purification procedure, which 
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gives a highly pure protein without any FHRs contamination, starting from 
total human serum. 
The availability of highly purified FH was an important feature for the 
development of FH-specific assays. 
An ELISA assay for specific quantification of serum FH using the purified 
MAb 5H5 in solid phase together with a chicken polyclonal antibody to FH, 
also produced in our lab, and 5H5-affinity purified FH as a standard was 
developed. A correct quantification of FH levels in samples from a number 
of diseases due to complement defects is a crucial point. Methods for the 
quantification of serum FH are often not specific as they recognise both FH 
and FHRs proteins and are therefore unreliable. The first quantifications 
based on polyclonal antibodies overestimated FH plasma concentration 
that were reported to be in the range of 115–685 μg/ml and sometimes 
even to 1 mg/ml, more recent studies using monoclonal antibodies have 
established mean FH concentrations around 233 μg/ml (in young adults) 
and 269 μg/ml (in elderly individuals) [143].  
The assay developed turned out to be specific and reliable and was then 
used to quantify FH from different samples. It was first used to quantify FH 
serum levels from aHUS patients revealing a FH deficit in four patients.  
Subsequently it was also used to quantify FH levels in different samples 
from AMD patients such as plasma, aqueous and vitreous humour.  
A micromethod to purify FH from small amounts of sample was developed 
using 5H5-coupled Sepharose resin and further improved by the use of 
Micro Bio-Spin™ Columns (Bio-Rad) which allow for a faster procedure. 
This method resulted to be really efficient enabling to obtain enough 
material for structural and functional studies which require the use of 
purified proteins. 
Most importantly, it has the advantage of reducing the amount of serum 
needed for FH purification. This is an important feature considering the fact 
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that FH-related diseases, e.g. aHUS, affect mainly children and the material 
available is poor. 
FH can be cleaved by a plasmatic protease into two fragments that are held 
together by a disulphide bond, this can be mimicked in vitro by trypsin. 
The ability of MAb 5H5 to recognise both the intact and the trypsin-cleaved 
form of FH, was demonstrated by IP and further exploited to set up an 
integrity assay to be used on different samples. The analysis on aHUS 
patients revealed that they all possess the intact form, whereas analysis on 
chromatography purified FH revealed the presence of the cleaved form. 
The question whether the cleaved FH form has a reduced activity is still 
controversial. The cut is within the SCR6 domain and separates the 
domains with cofactor activity from the rest of the molecule, even if the 
structure is still held together by disulfide bridges. 
It has been shown that the cofactor activity resides in the 38 KDa N-
terminal fragment and that this fragment is also able to work alone [168]. 
However, the data available in the literature on the cofactor activity of the 
cleaved form are different and often conflicting. Some works show that the 
cofactor activity in the fluid phase seems to be increased by the cleavage, 
whereas the cofactor activity for the degradation of membrane-bound C3b 
is certainly decreased [169].  
The presence of the cleaved form could also be due to an artefact of the 
purification methods.  
During the various steps, necessary for FH purification with biochemical 
methods, the plasmatic protease inhibitor is first removed thus enabling 
the plasmatic protease to cut FH.  
With affinity purification methods, such as the method developed here 
based on MAb 5H5, the presence of the cleaved form is generally not 
observed. Thus, the integrity test is an important tool to assess the 
presence of the cleaved form especially in those FH preparations obtained 
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with biochemical methods that are used to prepare FH for substitution 
therapies. 
The ability of MAb 5H5 to bind with the same affinity both the intact and 
the cleaved form of FH is probably due to the fact that this antibody 
recognises a structural epitope that remains the same in the two forms but 
is lost after reduction of disulphide bridges. In fact, MAb 5H5 recognises FH 
only under unreducing conditions. This feature is probably also the reason 
why MAb 5H5 is specific for FH and does not recognise any of the FHRs 
proteins. 
The epitope recognised by MAb 5H5 has not yet been identified; being a 
conformational mapping the epitope is challenging. Recombinant proteins 
that are discussed later, will be probably useful for this purpose. 
Finally, MAb 5H5 was used to develop two functional assays to assess both 
the N-terminal cofactorial activity and C-terminal protective activity of FH. 
The “cofactor assay” is based on the fact that FI can cut C3b in vitro only in 
the presence of a functional FH; if CFH is not functional C3b cannot be 
cleaved. The test was set up using purified C3b and FI together with 
different amounts of affinity purified FH. The test was used to screen 
different serum samples or fractions derived from a biochemical 
purification of FH and revealed a reduced activity in samples which 
underwent different chromatography steps. 
This reduced activity is probably due to the long procedure used to purify 
FH, consisting in two sequential chromatography steps, that somehow 
modify the protein. It doesn’t appear to be related to the presence of the 
cleaved form, but it is probably due to other modifications that occur in the 
protein during the procedure. 
The “Haemolysis test” is useful to assess the protective activity of FH that is 
dependent on the C-terminal part of the molecule. This test is based on the 
fact that FH is able to protect erythrocytes from complement attack; in the 
absence of FH or in the presence of a defective FH erythrocytes undergo 
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lysis which can be measured spectrophotometrically following the release 
of haemoglobin. The test will be performed making use of FH-depleted 
serum, which causes lysis of the erythrocytes, and 5H5-affinity purified FH 
from patient’s sera in order to assess the ability of those FH to restore 
protection. 
For the moment the assay has been set up using a normal control serum in 
order to test all the conditions. It was first necessary to test different buffer 
preparations as the correct buffer needed for this kind of test is not 
commercially available in Italy. FH is an important inhibitor of complement 
activation and its depletion from serum causes the indiscriminate 
activation of complement leading to the consumption of complement 
proteins. To avoid this activation that would render FH-depleted serum 
useless for this test, it is necessary to produce it in the presence of EDTA 
that blocks both the CP and the AP. However, the presence of EDTA will 
inhibit erythrocytes lysis thus precluding the possibility to perform the 
“Haemolysis test”. For these reasons it was necessary to perform the test 
in the presence of different concentrations of EDTA in order to establish 
the minimum concentration that still prevents complement to be activated 
in serum but allows the test to function. The set up of the last conditions 
needed to perform the final test is still under development. 
This test will be useful to assess N-terminal functionality especially in aHUS 
patients in which most mutations are located in the last two SCRs (SCR 19-
20) and cause haemolysis. The genetic characterisation of this group of 
aHUS  patients has already been performed whereas functional data at 
protein level are still missing. Therefore, the functional data obtainable 
with  this test will be fundamental to complement the characterisation of 
these patients and their relatives performed by DNA sequencing, thus 
allowing for a detailed description of the structure-function relationship. 
The other aim of this project was the cloning and expression of FH in both 
an eukaryotic and a prokaryotic system. 
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As FH is a glycoprotein and a correct glycosylation might be important for 
all its functions, I planned to use a modified insect expression system in 
which the glycosylation pattern is very similar to that of humans. 
Unglycosylated proteins to be used as a control will be produced in E. coli. 
FH is a big soluble protein with 20 SCR domains of about 60 aa each that 
bear different functions. I decided to clone separately both the entire 
protein and three main fragments containing approximately 7 SCR each 
(SCR 1-7, SCR 8-14, SCR 15-20). 
Four clones containing respectively the entire FH and the three fragments 
were obtained and confirmed by sequencing to possess the correct 
sequences. These clones will be used to produce the recombinant proteins 
into the two different systems. 
The recombinant proteins produced will be useful for different purposes. 
First of all they can be used to screen which parts of FH are involved in 
interaction with proteins of known pathogens and to explore interaction 
with other pathogens. Secondly their ability to restore the function of a 
defective FH or to protect against FH autoantibodies will be analysed. The 
final goal is to use them for therapy in many diseases caused by CFH 
defects for which the only possible treatment is currently plasma exchange. 
Furthermore, these recombinant fragments will also be used to try to 
identify the so far elusive conformational epitope recognised by MAb 5H5. 
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CONCLUSIONS 
The study of complement factor H (FH) is complicated by the presence of 
FHR proteins that share a high degree of similarity.  
Thanks to the use of a monoclonal antibody (MAb 5H5) produced in our 
lab, and shown to be specific for FH, it was possible to develop several FH-
specific tests. 
A fast and efficient method for the purification of FH was developed and 
further scaled down to be applicable to small samples. A home-made ELISA 
for the correct quantification of FH in biological fluids, without any 
interference from FHR proteins, was developed and used to screen 
different samples. A test for the assessment of FH structural integrity, 
based on the fact that FH can be cleaved by a protease into a probably less 
active form, was also developed. This test used to screen both FH purified 
from patient’s sera and samples deriving from different purification 
procedures. 
Finally two functional assays to test both the C-terminal cofactorial activity 
and the N-terminal protective activity of FH were developed. 
The “cofactor assay”, based on the fact that FI can cut its substrate C3b 
only in the presence of a functional FH, has been set up and was used to 
screen different samples. This test was important especially to assess 
functionality of some FH preparations obtained with a biochemical 
purification method, that were intended to be used for therapeutic 
purposes. 
The second one, the “haemolysis test” based on the fact that a functional 
FH is able to protect sheep erythrocytes from haemolysis, is now in its fine 
tuning phase. This test is a modification of a test normally used to assess 
AP activation in sera. For the test a FH-depleted serum from a normal 
subject will be used together with FH purified from patients. 
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The developed tests that have been used in the present work on aHUS 
patients and FH preparations produced for therapeutic purposes, will be 
used in the future also for a bigger screening on AMD patients for whom a 
pilot study just started. The study of AMD patients will be part of a larger 
project that will involve other methods such as the study of retinal 
epithelial cells which have been shown to produce FH locally in the eye [86] 
and the genetic screening of some SNPs which have been shown to 
correlate with the development of the disease [138]. 
Another aim of this project was the cloning of the entire FH and some 
fragments for the expression into both a prokaryotic and a eukaryotic 
system in order to produce both glycosylated and unglycosylated proteins. 
The clones have been produced and are ready to be introduced into the 
expression hosts. 
The recombinant proteins produced will be useful for different purposes. 
First of all they can be used to screen which parts of FH are involved in 
interaction with proteins of known pathogens and to explore interaction 
with other pathogens. Secondly their ability to restore the function of a 
defective FH or to protect against FH autoantibodies will be analysed. The 
final goal is to use them for therapy in many diseases caused by FH defects 
for which the only possible treatment is currently plasma exchange 
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APPENDIX 
A. Factor H ELISA 
BUFFERS: 
Coating buffer: TBS, pH 7.65 
Wash buffer: TBS/Tween 0.1% 
Overcoating buffer: 3% BSA in TBS/Tween 0.5% (TTBS) 
Sample buffer: TBS-BSA 1%, Tween 0.1% 
 
PROTOCOL 
1. Coating:  
- Dilute MAb 5H5 stock solution (3 mg/ml) to 1:2000 in Coating buffer 
to give a final concentration of 1.5 µg/ml 
- Dispense 100 µl/well in a microtiter plate and incubate o/n at 4°C 
Wash the plate three times with Wash buffer  
2. Overcoating:  
- Dispense 250 µl/well of Overcoating buffer  
- Incubate 1 h at 37°C in an Eppendorf Thermomixer 
Wash the plate three times with Wash buffer  
3. Samples:  
- Dilute the samples, control and standard in Sample buffer 
∗ Standard Curve: 
5H5-affinity purified FH (1 µg/µl) 
- prepare 5 two-fold serial dilutions starting from 250 ng/ml 
- Dispense 100 µl/well to the assigned microassay wells in 
triplicate 
∗ Samples:  
Plasma or sera 
- prepare 3 dilutions: 1:2.000, 1:4.000 and 1:8.000 
- Dispense 100 µl/well to the assigned microassay wells in 
duplicate 
∗ Positive Control:  
5H5-affinity purified FH (174 µg/ml) 
- prepare 3 dilutions: 1:2.000, 1:4.000 and 1:8.000 
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- Dispense 100 µl/well to the assigned microassay wells in 
duplicate 
- Reserve two wells for blank, 100 µl/well of Sample buffer 
- Incubate 1 h at 37°C in an Eppendorf Thermomixer 
Wash the plate three times with Wash buffer  
4. Primary antibody:  
- Dilute the Chicken anti-FH antibody 1:25.000 in Sample buffer  
- Dispense 100 µl/well  
- Incubate 1 h at 37°C in an Eppendorf Thermomixer 
Wash the plate three times with Wash buffer  
5. Secondary antibody:  
- Dilute the anti-chicken IgY-HRP antibody (Promega) 1:5.000 in 
Sample buffer 
- Dispense 100 µl/well 
- Incubate 1 h at 37°C in an Eppendorf Thermomixer 
Wash the plate three times with Wash buffer  
6. Develop:  
- Prepare the Substrate Solution: Warm the reagent to room 
temperature before use. Mix equal volumes (5 ml) of TMB Peroxidase 
Substrate and Peroxidase Substrate Solution B (KPL) immediately 
prior to use.  
(Note: TMB Peroxidase Substrate contains 3,3',5,5'- tetramethylbenzidine at 
a concentration of 0.4 g/L in an organic base. Peroxidase Substrate Solution B 
contains H202 at a concentration of 0.02% in a Citric Acid buffer.) 
- Dispense 100 µl/well 
- Incubate at 37°C in an Eppendorf Thermomixer 
- Read the plate in Microplate Reader (Model 680 Bio-Rad) at 595 nm, 
after 20 and 40 min. 
7. Stop:  
- Stop the reaction with 100 µl/well of Stop Solution (2N Sulphuric 
Acid), solution will turn yellow 
- Read the plate in Microplate Reader (Model 680 Bio-Rad) at 450 nm 
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B. Haemolysis test 
Buffers: 
• V-AP Buffer (Veronal) 1X: Veronal 1X + 5 mM MgCl2 + 10 mM EGTA + 
0.1% gelatin 
Veronal Buffer 5X (Lonza): Barbitol 15.58 mM, Sodium Barbitol 9.07 mM, 
NaCl 727.24 mM, CaCl2 1.26 mM, MgCl2 4.13 mM 
• H-AP Buffer (Hepes) 1X: Hepes 1X + 6 mM MgCl2 + 10 mM EGTA + 0.1% 
gelatin 
Hepes Buffer (5X): HEPES 21 mM, NaCl 725 mM 
• N-Saline: 154 mM NaCl 
 
Preparation of Sheep Erythrocytes (Esh) for Alternative Pathway Assay 
1. Under aseptic conditions, remove 0.5 ml packed Sheep Erythrocytes 
from stock stored in Alsever’s solution (Sigma). 
2. Wash in Alsever’s solution (several times) 
3. Count Erythrocytes and transfer a part into a new tube with AP buffer 
(NOTE: Erythrocytes were divided into two different tubes containing the two 
AP buffers: V-AP and H-AP) 
4. Wash in AP buffer 
5. Resuspend in the same buffer to the required concentration for assay 
(10
8
/ml) 
Protocol 
1. Prepare one set of disposable 1,5ml tubes for serum dilutions and one 
set of disposable 2ml tubes for the assay. Include in the assay-rack 
tubes for 0% controls and for total-lysis controls. Place tubes on ice. 
(NOTE: two different set for the two different AP buffers were prepared) 
2. Prepare six serial 1.5-fold dilutions of serum sample starting from 1:4 
in ice-cold AP buffer, mixing well after each dilution before doing the 
next. 
3. Add 100 μl of ESh suspension (in AP buffer at 10
8
/mL) to each assay 
tube. 
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4. Transfer 100 µl of each dilution to the appropriate tube in the assay 
rack. Place 100 µl AP buffer in the background-lysis control tubes. 
5. Incubate 60 min at 37°C with occasional shaking to keep the cells in 
suspension. 
6. To all serum tubes and background-lysis control tubes add 300 μl ice-
cold N-saline to stop the reaction, to total-lysis control tubes add 400 
μl H20. 
7. Centrifuge 5 min at 1000 × g, 4°C, to pellet the cells. 
8. Read the OD415 of each supernatant (200 μl in duplicate wells) 
Calculations: 
1. Subtract background-lysis control absorbance from each value to obtain 
corrected absorbances (Abc) 
2. Calculate fractional haemolysis in each well relative to the 100% lysis 
wells: Fractional haemolysis (y) = (Abc serum/Abc 100%) 
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